Synthesis of TYK2 inhibitor and intermediates thereof

The preparation of selective TYK2 inhibitors through improved synthetic methods has solved the problems of insufficient supply and safety of TYK2 inhibitors in the prior art, and achieved more efficient TYK2 inhibition and longer treatment periods, which are suitable for the treatment of inflammatory and autoimmune Sexual disease.

CN118922420APending Publication Date: 2024-11-08TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029503.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-25
Filing Date
2023-03-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing TYK2 inhibitors have not been able to effectively provide a large number of compounds for clinical research and treatment, and there are safety issues and side effects associated with JAK inhibitors, making it difficult to directly and specifically inhibit TYK2 function.

Method used

By providing a synthetic method of oral allosterically selective TYK2 inhibitors, the preparation of compound 1 and its pharmaceutically acceptable salts or solvates is achieved by providing an improved synthesis procedure to achieve higher selectivity and stability, avoiding JAK Safety issues related to inhibitors.

Benefits of technology

Achieve higher TYK2 inhibition levels and longer treatment periods, providing clinical and commercial advantages, and reducing the safety risks associated with JAK inhibitors, suitable for the treatment of psoriasis, psoriatic arthritis and other inflammatory and autoimmune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005054743810000031
    Figure BDA0005054743810000031
  • Figure BDA0005054743810000032
    Figure BDA0005054743810000032
  • Figure BDA0005054743810000041
    Figure BDA0005054743810000041
Patent Text Reader

Abstract

Methods of synthesizing tyrosine-protein kinase 2 (TYK2) inhibitors and intermediate compounds of the synthesis and methods of making the intermediates are described herein. Also provided are pharmaceutically acceptable compositions comprising the compounds prepared by the synthetic methods and methods of using the compositions in the treatment of conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority claim

[0002] This application claims priority to U.S. Provisional Application No. 63 / 269,946, filed on March 25, 2022, the entire contents of which are hereby incorporated by reference. Technical Field

[0003] The present disclosure relates to a synthesis method of a tyrosine-protein kinase 2 (TYK2) inhibitor and an intermediate compound of the synthesis and a method for preparing the intermediate. Also provided are a pharmaceutically acceptable composition comprising a compound prepared by the synthesis method and a method for treating a disease using the composition. Background Art

[0004] Protein kinases constitute a large family of structurally related enzymes responsible for controlling a variety of signal transduction processes in cells. Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar catalytic domain of 250-300 amino acids. They can be classified into many families according to the substrates phosphorylated by the kinases (e.g., protein-tyrosine, protein-serine / threonine, lipids, etc.).

[0005] In general, protein kinases mediate intracellular signal transduction by achieving phosphoryl transfer from nucleoside triphosphates to protein receptors involved in signal transduction pathways. These phosphorylation events act as molecular on / off switches that can regulate or control target protein biological functions. These phosphorylation events are ultimately triggered in response to a variety of extracellular stimuli and other stimuli. Examples of such stimuli include environmental and chemical stress signals (e.g., osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxins, and H 2 O 2 ), cytokines (e.g., interleukin-1 (IL-1), interleukin-8 (IL-8), and tumor necrosis factor α (TNF-α)), and growth factors (e.g., granulocyte macrophage colony stimulating factor (GM-CSF) and fibroblast growth factor (FGF)). Extracellular stimuli can affect one or more cellular responses related to cell growth, migration, differentiation, hormone secretion, transcription factor activation, muscle contraction, glucose metabolism, control of protein synthesis, and regulation of the cell cycle.

[0006] Many diseases are associated with abnormal cellular responses triggered by kinase-mediated events. These diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases.

[0007] TYK2 catalyzes the phosphorylation of STAT proteins downstream of multiple cytokine receptors, including type I interferon receptors and IL-12 and IL-23 receptors. TYK2-dependent receptors are activated by their cytokine ligands, leading to STAT-dependent transcription and activation of cell function responses specific to the receptors and the cell types expressing the receptors. The cytokine signaling pathways regulated by TYK2 play a key role in several immune-mediated disorders. Cytokine IL-12 is essential for the development of type 1 T helper cells (Th1), which produce interferon-γ, a major effector molecule in systemic autoimmune disorders such as systemic lupus erythematosus. Cytokine IL-23 is essential for the expansion and survival of Th17 cells and innate lymphoid cells, and the two cells have been shown to play a key pathogenic role in autoimmunity. IL-23 stimulation drives Th17 cells to produce key proinflammatory cytokines, including IL-17A, IL-17F, and IL-22, all of which are effector molecules important in the pathogenesis of conditions such as psoriasis, psoriatic arthritis, and spondyloarthritis. Because TYK2 has effects on the IL-23 / Th17 / Th22 axis, IL-12-mediated Th1 function, and type I interferon-driven regulation of different immune pathways and cell types, inhibition of TYK2 is expected to affect a variety of immune-mediated conditions.

[0008] Compound 1:

[0009]

[0010] is a TYK2 inhibitor. See U.S. Patent No. 11,046,698. There remains a need for a synthetic method that can effectively provide large quantities (e.g., kilogram scale or greater) of Compound 1 for further clinical research and treatment. The present disclosure meets this need and provides other related advantages. Summary of the invention

[0011] In one aspect, described herein is compound 1 produced by the methods disclosed herein:

[0012]

[0013] or a pharmaceutically acceptable salt or solvate thereof.

[0014] In one aspect, described herein is a method for preparing Compound 1:

[0015]

[0016] or a pharmaceutically acceptable salt or solvate thereof.

[0017] In another aspect, described herein are methods for preparing compounds of formula I:

[0018]

[0019] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group as defined herein.

[0020] In another aspect, described herein are methods for preparing compounds of formula II:

[0021]

[0022] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group as defined herein.

[0023] In one aspect, described herein is a compound of formula I:

[0024]

[0025] or a pharmaceutically acceptable salt thereof, wherein:

[0026] PG is a suitable amino protecting group.

[0027] In one aspect, described herein is a compound of formula II:

[0028]

[0029] or a pharmaceutically acceptable salt thereof, wherein:

[0030] PG is a suitable amino protecting group as defined herein.

[0031] In another aspect, a method of inhibiting TYK2 protein kinase or a mutant thereof in a patient is described; the method comprising administering to the patient a therapeutically effective amount of Compound 1:

[0032]

[0033] or a pharmaceutically acceptable salt or solvate thereof, wherein Compound 1 is produced by the method described herein.

[0034] Other aspects, embodiments, and features will be apparent from the following description, drawings, and claims. DETAILED DESCRIPTION

[0035] Compound 1 described below is an oral allosteric selective TYK2 inhibitor for the treatment of psoriasis, psoriatic arthritis, and other inflammatory and autoimmune diseases. There are currently no approved TYK2 inhibitors, and Compound 1 is the most selective TYK2 inhibitor currently in clinical development. In addition, the selectivity of Compound 1 and the potential for once-daily (QD) dosing to provide higher TYK2 inhibition levels over a longer period of time may give it a clinical and ultimate commercial advantage over other TYK2 inhibitors in development. TYK2 is a member of the Janus kinase (JAK) kinase family, which is a class of intracellular signaling proteins that regulate chronic inflammation in inflammatory and autoimmune diseases. Although JAK inhibition can effectively treat inflammatory and autoimmune diseases, it can also produce on-target safety issues due to the regulation of a wide variety of cytokine pathways. Therefore, although JAK inhibitors have become established oral treatments for a wide variety of inflammatory and autoimmune diseases, their clinical utility is limited by the increased risk of infection and other side effects, which has led the US Food and Drug Administration (FDA) to mandate boxed warnings and dosing restrictions as part of the labeling of the inhibitors. Due to the structural similarities between the catalytic (orthosteric or JH1) sites targeted by drugs on the JAK catalytic domain, it is challenging to design selective JAK inhibitors that directly and specifically inhibit the intended kinase function. Based on human genetic data and increasing clinical evidence of the selectivity of allosteric TYK2 inhibitors, the method of selective allosteric inhibition of TYK2 of the present invention provides an optimal balance of achieving strong efficacy while potentially avoiding safety issues associated with broader JAK inhibition for the treatment of a variety of inflammatory and autoimmune diseases. Therefore, a robust, scalable and enantioselective synthetic procedure to generate compounds for further testing is important for the use of the compounds in research and clinical settings.

[0036] U.S. Patent No. 11,046,698 (the entire contents of which are hereby incorporated by reference) describes certain therapeutically beneficial compounds. Such compounds include Compound 1:

[0037]

[0038] or a pharmaceutically acceptable salt thereof.

[0039] Compound 1 is designated as I-908 in US 11,046,698, and an alternative synthesis of Compound 1 (which differs from the improved synthesis described herein) is described in detail in Example 40 of US 11,046,698. It would be desirable to provide an improved method for synthesizing Compound 1 or a pharmaceutically acceptable salt or solvate thereof. Therefore, methods for synthesizing such compounds and pharmaceutically acceptable salts thereof are described herein.

[0040] In some embodiments, improved methods of preparing Compound 1, or a pharmaceutically acceptable salt or solvate thereof, are described, wherein such methods produce Compound 1 with higher yields, fewer steps, milder conditions, and / or greater versatility (greater structural variation of the desired compound). In some embodiments, methods of preparing Compound 1, or a pharmaceutically acceptable salt or solvate thereof, are described, as further described herein.

[0041] In another aspect, provided are intermediates useful for preparing Compound 1. Such intermediates include those described in detail below.

[0042] In another aspect, compound 1 or a pharmaceutically acceptable salt or solvate thereof is described herein, characterized in that the compound is prepared according to the synthetic method described herein. In another aspect, a pharmaceutical composition comprising compound 1 or a pharmaceutically acceptable salt or solvate thereof is described, characterized in that the compound is prepared according to the synthetic method described herein.

[0043] The compounds prepared by the methods herein, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, can be used to treat, prevent, ameliorate, or accelerate recovery from a variety of injuries, diseases, and conditions, including those described herein.

[0044] Compounds and Definitions

[0045] Compounds include those generally described herein and are further described by the classes, subclasses, and species disclosed herein. Unless otherwise indicated, as used herein, the following definitions shall apply. For the purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements (CAS version, Handbook of Chemistry and Physics, 75th edition). In addition, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999; and "March's Advanced Organic Chemistry", 5th edition, editors: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0046] As used herein, the term "aliphatic" or "aliphatic group" means a straight chain (i.e., unbranched) or branched substituted or unsubstituted hydrocarbon chain that is completely saturated or contains one or more unsaturated units, or a monocyclic hydrocarbon or bicyclic hydrocarbon (also referred to herein as "carbocycle" or "cycloaliphatic") that is completely saturated or contains one or more unsaturated units, but is not aromatic, which has a single point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle") refers to a monocyclic C 2-1 ... 3 -C 6 A hydrocarbon having a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.

[0047] As used herein, the term "bicyclic" or "bicyclic system" refers to any bicyclic system, i.e., carbocyclic or heterocyclic, saturated or with one or more unsaturated units, with one or more common atoms between the two rings of the ring system. Therefore, the term includes any allowed ring fusion, such as ortho-fused or spirocyclic. As used herein, the term "heterobicyclic" is a subset of "bicyclic", which requires one or more heteroatoms to be present in one or both rings of the bicyclic. Such heteroatoms may be present at the ring junction and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In some embodiments, the bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. As used herein, the term "bridged bicyclic" refers to any bicyclic system with at least one bridge, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated. As defined by IUPAC, "bridge" is an unbranched atomic chain or atom or valence bond connecting two bridgeheads, wherein "bridgehead" is any backbone atom bonded to three or more backbone atoms (excluding hydrogen) in a ring system. In some embodiments, the bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Such bridged bicyclic groups are well known in the art, and include those groups described below, wherein each group is connected to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise indicated, the bridged bicyclic group is optionally substituted by one or more substituents as described for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of the bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:

[0048]

[0049] Exemplary bridged double rings include:

[0050]

[0051] The term "lower alkyl" refers to a C 1-4 Straight or branched chain alkyl. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0052] The term "lower haloalkyl" refers to a C 1-4 Straight chain or branched chain alkyl.

[0053] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR +(as in N-substituted pyrrolidinyl)).

[0054] As used herein, the term "unsaturated" means that the moiety has one or more units of unsaturation.

[0055] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH 2 ) n -, wherein n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2 or 2 to 3. A "substituted" alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0056] The term "alkenylene" refers to a divalent alkenyl group having at least one carbon-carbon double bond. Unless otherwise indicated, the double bond may be cis or trans. In some embodiments, the alkenylene has a single carbon-carbon double bond. In some embodiments, the double bond is cis. In some embodiments, the double bond is trans. A substituted alkenylene chain is a polymethylene containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0057] The term "alkynylene" refers to a divalent alkynyl group having at least one carbon-carbon triple bond. The carbon-carbon triple bond may be located in an interior or terminal position of the alkynylene group, i.e., between two carbon atoms or carbon atoms at either end or in the interior of the chain. A substituted alkenylene chain is a polymethylene group containing at least one triple bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups. In some embodiments, the triple bond is located in a terminal position and the alkynyl hydrogens are optionally replaced by substituents.

[0058] The term "halogen" means F, Cl, Br or I.

[0059] The term "aryl" used alone or as part of a larger moiety (as in "aralkyl", "aralkyloxy" or "aryloxyalkyl") refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" can be used interchangeably with the term "aryl ring". In certain embodiments, "aryl" refers to an aromatic ring system, which includes but is not limited to phenyl, biphenyl, naphthyl, anthracenyl, etc., which may bear one or more substituents. As used herein, the term "aryl" also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, such as dihydroindanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, etc.

[0060] The terms "heteroaryl" and "heteroar-" (e.g., "heteroaralkyl" or "heteroaralkoxy"), used alone or as part of a larger moiety, refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of basic nitrogen. Heteroaryl includes, but is not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. As used herein, the terms "heteroaryl" and "heteroaryl-" also include groups in which a heteroaromatic ring is fused to one or more aryl rings, cycloaliphatic rings, or heterocyclyl rings, wherein the connecting group or point of attachment is located on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, and pyrido [2,3-b] -1,4-oxazine-3 (4H) -one. The heteroaryl group may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which includes rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group, wherein the alkyl and heteroaryl portions are independently optionally substituted.

[0061] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical" and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety which is saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four heteroatoms as defined above. The term "nitrogen" when used with respect to a ring atom of a heterocycle includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or + NR (as in N-substituted pyrrolidinyl).

[0062] The heterocycle may be attached to its side group at any heteroatom or carbon atom that produces a stable structure, and any one of the ring atoms may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrophenylthio, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepine, oxazepine, thiazepine, morpholinyl, and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl. The heterocyclyl group may be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group, wherein the alkyl and heterocyclyl moieties are independently optionally substituted.

[0063] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.

[0064] As described herein, compounds may contain "optionally substituted" parts. In general, the term "substituted" means that one or more hydrogens of the specified part are replaced by suitable substituents, regardless of whether there is a preceding term "optionally". Unless otherwise indicated, the "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from a specified group, the substituent at each position may be the same or different. The contemplated substituent combinations are preferably those that form stable or chemically feasible compounds. As used herein, the term "stable" means that for one or more purposes disclosed herein, the compound does not undergo substantial changes when subjected to conditions that allow it to be produced, detected, and in certain embodiments, to be recovered, purified, and used.

[0065] Each optional substituent on a substitutable carbon is independently a monovalent substituent selected from the group consisting of halogen; -(CH 2 ) 0-4 R o ;-(CH 2 ) 0-4 OR o ; -O(CH 2 ) 0-4 Ro ,-O-(CH 2 ) 0-4 C(O)OR o ;-(CH 2 ) 0-4 CH(OR o ) 2 ;-(CH 2 ) 0- 4 SR o ;-(CH 2 ) 0-4 Ph, which can be o Substitution; -(CH 2 ) 0-4 O(CH 2 ) 0-1 Ph, which can be o Substitution; -CH=CHPh, which can be R o Substitution; -(CH 2 ) 0-4 O(CH 2 ) 0-1 -pyridyl, which may be R o Replacement; -NO 2 ;-CN;-N 3 ;-(CH 2 ) 0-4 N(R o ) 2 ;-(CH 2 ) 0-4 N(R o )C(O)R o ;-N(R o )C(S)R o ;-(CH 2 ) 0-4 N(R o )C(O)NR o 2 ;-N(R o )C(S)NR o 2 ;-(CH 2 ) 0-4 N(R o )C(O)OR o ;-N(R o )N(R o )C(O)R o ;-N(R o )N(R o )C(O)NR o 2 ;-N(R o )N(R o)C(O)OR o ;-(CH 2 ) 0-4 C(O)R o ;-C(S)R o ;-(CH 2 ) 0-4 C(O)OR o ;-(CH 2 ) 0-4 C(O)SR o ;-(CH 2 ) 0-4 C(O)OSiR o 3 ;-(C H 2 ) 0-4 OC(O)R o ;-OC(O)(CH 2 ) 0-4 SR-,SC(S)SR o ;-(CH 2 ) 0-4 SC(O)R o ;-(CH 2 ) 0-4 C(O)NR o 2 ;-C(S)NR o 2 ;-C(S)SR o ;-SC(S)SR o ;-(CH 2 ) 0-4 OC(O)NR o 2 ;-C(O)N(OR o )R o ;-C(O)C(O)R o ;-C(O)CH 2 C(O)R o ;-C(NOR o )R o ;-(CH 2 ) 0-4 SSR o ;-(CH 2 ) 0-4 S(O) 2 R o ;-(CH 2 ) 0-4 S(O) 2 OR o ;-(CH 2 ) 0-4 O S(O) 2 Ro ; -S(O) 2 NR o 2 ;-(CH 2 ) 0- 4 S(O)R o ;-N(R o )S(O) 2 NR o 2 ;-N(R o )S(O) 2 R o ;-N(OR o )R o ; -C(NH)NR o 2 ;-P(O) 2 R o ;-P(O)R o 2 ;-OP(O)R o 2 ;-OP(O)(OR o ) 2 ;SiR o 3 ;-(C 1-4 Straight or branched alkylene)ON(R o ) 2 ; or -(C 1-4 Straight or branched alkylene)C(O)ON(R o ) 2 .

[0066] Each R o are independently hydrogen, C 1-6 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph, -CH 2 -(5-6 membered heteroaryl ring) or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definitions, two independent occurrences of R o Together with one or more of its intermediate atoms, it forms a 3-12-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which can be replaced by R o A saturated carbon atom of o Optionally substituted with monovalent substituents independently selected from halogen, -(CH 2 ) 0-2 R ·、-(halogen R · )、-(CH 2 ) 0-2 OH, -(CH 2 ) 0-2 OR · 、-(CH 2 ) 0-2 CH(OR · ) 2 、-O(halogen R · ), -CN, -N 3 、-(CH 2 ) 0-2 C(O)R · 、-(CH 2 ) 0-2 C(O)OH, -(CH 2 ) 0-2 C(O)OR · 、-(CH 2 ) 0-2 SR · 、-(CH 2 ) 0- 2 SH, -(CH 2 ) 0-2 NH 2 、-(CH 2 ) 0-2 NHR · 、-(CH 2 ) 0-2 NR · 2 、-NO 2 、-SiR · 3 、-OSiR · 3 、-C(O)SR · 、-(C 1-4 Straight or branched alkylene)C(O)OR · or -SSR · .

[0067] Each R · Independently selected from C 1-4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R ·unsubstituted or, if preceded by a halogen, substituted only with one or more halogens; or wherein the optional substituents on the saturated carbon are divalent substituents independently selected from the group consisting of: =O, =S, =NNR * 2 、=NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O) 2 R * , =NR * , =NOR * 、-O(C(R * 2 )) 2-3 O-or-S(C(R * 2 )) 2-3 S-, or a divalent substituent attached to an ortho-substitutable carbon of an "optionally substituted" group is -O(CR * 2 ) 2-3 O-, where each independent occurrence of R * Selected from hydrogen, C 1-6 Aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0068] When R * C 1-6 When aliphatic, R * Optionally halogen, -R · 、-(halogen R · ), -OH, -OR · 、-O(halogen R · )、-CN、-C(O)OH、-C(O)OR · 、-NH 2 、-NHR · 、-NR · 2 or-NO 2 Substitute, where each R · Independently selected from C 1-4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R · Unsubstituted or, when preceded by a halo, substituted only by one or more halogens.

[0069] The optional substituents on the substitutable nitrogen are independently or Each of these are independently hydrogen, C 1-6 aliphatic, unsubstituted -OPh or an unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or two independent occurrences of Together with one or more of its intermediate atoms, it forms an unsubstituted 3-12-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; wherein when C 1-6 When aliphatic, Optionally halogen, -R · 、-(halogen R · ), -OH, -OR · 、-O(halogen R · )、-CN、-C(O)OH、-C(O)OR · 、-NH 2 、-NHR · 、-NR · 2 or-NO 2 Substitute, where each R · Independently selected from C 1-4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R · Unsubstituted or, when preceded by a halo, substituted only by one or more halogens.

[0070] As used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with human and lower animal tissues within the scope of reasonable medical judgment without excessive toxicity, irritation, allergic reaction, etc. and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of compounds include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed of amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid), or by using other methods used in the art (such as ion exchange method) formed salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.

[0071] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 alkyl) 4 Salts. Representative alkali metal salts or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, etc. Other pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.

[0072] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the compounds of the invention are contemplated. Unless otherwise stated, all tautomeric forms of the compounds are contemplated. In addition, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, structures having the present invention (including replacement of hydrogen with deuterium or tritium, or replacement of hydrogen with isotopically enriched atoms) are contemplated. 13 C or 14 Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents.

[0073] Description of Exemplary Embodiments

[0074] In one aspect, Compound 1 produced by the methods disclosed herein is described:

[0075]

[0076] or a pharmaceutically acceptable salt or solvate thereof.

[0077] In one aspect, a compound of formula I is described:

[0078]

[0079] or a pharmaceutically acceptable salt thereof, wherein:

[0080] PG is a suitable amino protecting group.

[0081] In certain embodiments, PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl. In certain embodiments, PG is tert-butyloxycarbonyl (BOC).

[0082] In one aspect, Compound 2 is described:

[0083]

[0084] or a pharmaceutically acceptable salt thereof.

[0085] In one aspect, compounds of formula II are described:

[0086]

[0087] or a pharmaceutically acceptable salt thereof, wherein:

[0088] PG is a suitable amino protecting group.

[0089] In certain embodiments, PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl. In certain embodiments, PG is tert-butyloxycarbonyl (BOC).

[0090] In one aspect, compound 6 is described:

[0091]

[0092] or a pharmaceutically acceptable salt thereof.

[0093] In one aspect, compounds of formula III are described:

[0094]

[0095] or a pharmaceutically acceptable salt thereof, wherein:

[0096] PG is a suitable amino protecting group.

[0097] The compound of formula III can be obtained by compound 8:

[0098]

[0099] or N-protection of a pharmaceutically acceptable salt or ester thereof.

[0100] In one aspect, compound 1' produced by the methods disclosed herein is described:

[0101]

[0102] or a pharmaceutically acceptable salt or solvate thereof.

[0103] In one aspect, compounds of formula I' are described:

[0104]

[0105] or a pharmaceutically acceptable salt thereof, wherein:

[0106] PG is a suitable amino protecting group.

[0107] In certain embodiments, PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl. In certain embodiments, PG is tert-butyloxycarbonyl (BOC).

[0108] In one aspect, compound 2' is described:

[0109]

[0110] or a pharmaceutically acceptable salt thereof.

[0111] In one aspect, compounds of formula II' are described:

[0112]

[0113] or a pharmaceutically acceptable salt thereof, wherein:

[0114] PG is a suitable amino protecting group.

[0115] In certain embodiments, PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl. In certain embodiments, PG is tert-butyloxycarbonyl (BOC).

[0116] In one aspect, compound 6' is described:

[0117]

[0118] or a pharmaceutically acceptable salt thereof.

[0119] In one aspect, compounds of formula III are described:

[0120]

[0121] or a pharmaceutically acceptable salt thereof, wherein:

[0122] PG is a suitable amino protecting group.

[0123] The compound of formula III can be prepared by N-protection of compound 8:

[0124]

[0125] According to the embodiments described herein, the above-mentioned protecting groups (e.g., PG or PG 1 ) deprotection or the addition of protecting groups include those protecting groups and methods described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, the entire contents of which are incorporated herein by reference. In some embodiments, the protecting group is a suitable amino protecting group.

[0126] As used herein, the phrase "suitable amino protecting groups" are well known in the art and when taken together with the nitrogen to which they are attached include, but are not limited to, aralkylamines, carbamates, allylamines, amides, and the like. Examples of monoprotecting groups for amines include tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, benzoyl, and the like. The example of the diprotecting group of amine comprises the amine substituted by two substituents independently selected from those described above as monoprotecting groups, and also comprises cyclic imide, such as phthalimide, maleimide, succinimide, 2,2,5,5-tetramethyl-1,2,5-azadisilolidine, azide etc.It should be understood that after the amino protecting group acid hydrolysis, its salt compound is formed.For example, when the amino protecting group is removed by treatment with acid (such as hydrochloric acid), the amine compound obtained will be formed with the form of its hydrochloride.It will be appreciated by those of ordinary skill in the art that various acids can be used to remove the unstable amino protecting group of acid, and therefore various salt forms are considered.

[0127] In another aspect, a compound selected from any one of those in Table 1, or a pharmaceutically acceptable salt thereof, is described.

[0128] Table 1: Intermediates and one or more target compounds

[0129]

[0130]

[0131] Exemplary Synthesis Methods

[0132] As described above, provided herein are methods for synthesizing compound 1 and compounds of formula I, I', II, II' or III and pharmaceutically acceptable salts thereof. In some embodiments, the compounds of the present invention are generally prepared according to Scheme 1 listed below:

[0133] Solution 1

[0134]

[0135] In Scheme 1 above, PG is as defined and described in the embodiments herein, and includes nitrogen protecting groups well known to those of ordinary skill in the art.

[0136] In one aspect, a method for preparing Compound 1 is described:

[0137]

[0138] or a pharmaceutically acceptable salt or solvate thereof, the method comprising making a compound of formula I:

[0139]

[0140] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group.

[0141] In certain embodiments, PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl. In certain embodiments, PG is tert-butyloxycarbonyl (BOC).

[0142] In certain embodiments, the compound of Formula I is Compound 2:

[0143]

[0144] or a pharmaceutically acceptable salt thereof.

[0145] In some embodiments, deprotection comprises hydrogenolysis, contact with an acid (e.g., HCl), contact with a base (e.g., piperidine, ammonia, K 2 CO 3or methylamine) contact, or heating. According to the embodiments described herein, the deprotection of the above-mentioned protecting group (e.g., PG) is included in those protecting groups and methods for their deprotection described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, the entire contents of which are incorporated herein by reference. In some embodiments, the protecting group is a suitable amino protecting group. Deprotection can be carried out in any solvent described below. In some embodiments, deprotection is carried out in an alcohol selected from methanol, ethanol, propanol, butanol, pentanol or hexanol. In some embodiments, deprotection is carried out in ethanol.

[0146] In certain embodiments, the method comprises:

[0147] a) making a compound of formula II:

[0148]

[0149] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; and compound 4:

[0150]

[0151] Cross-coupling to produce a compound of formula I; and

[0152] b) making the compound of formula I:

[0153]

[0154] or a pharmaceutically acceptable salt thereof.

[0155] In certain embodiments, the compound of Formula II is Compound 6:

[0156]

[0157] or a pharmaceutically acceptable salt thereof.

[0158] In one aspect, a method for preparing compound 1' is described:

[0159]

[0160] or a pharmaceutically acceptable salt or solvate thereof, the method comprising making a compound of formula I':

[0161]

[0162] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group.

[0163] In certain embodiments, PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl. In certain embodiments, PG is tert-butyloxycarbonyl (BOC).

[0164] In certain embodiments, the compound of Formula I' is Compound 2':

[0165]

[0166] or a pharmaceutically acceptable salt thereof.

[0167] In some embodiments, deprotection comprises hydrogenolysis, contact with an acid (e.g., HCl), contact with a base (e.g., piperidine, ammonia, K 2 CO 3 or methylamine) contact, or heating. According to the embodiments described herein, the deprotection of the above-mentioned protecting group (e.g., PG) is included in those protecting groups and methods for their deprotection described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, the entire contents of which are incorporated herein by reference. In some embodiments, the protecting group is a suitable amino protecting group. Deprotection can be carried out in any solvent described below. In some embodiments, deprotection is carried out in an alcohol selected from methanol, ethanol, propanol, butanol, pentanol or hexanol. In some embodiments, deprotection is carried out in ethanol.

[0168] In certain embodiments, the method comprises:

[0169] c) making a compound of formula II':

[0170]

[0171] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; and compound 4:

[0172]

[0173] Cross-coupling to produce a compound of formula I'; and

[0174] d) making the compound of formula I':

[0175]

[0176] or a pharmaceutically acceptable salt thereof.

[0177] In certain embodiments, the compound of Formula II' is Compound 6':

[0178]

[0179] or a pharmaceutically acceptable salt thereof.

[0180] In some embodiments, the cross-coupling comprises a metal-catalyzed cross-coupling reaction. In certain embodiments, the cross-coupling comprises a palladium-catalyzed cross-coupling (e.g., Buchwald-Hartwig cross-coupling). In some embodiments, the method comprises contacting a palladium compound, a ligand, a compound of formula II or II, and compound 4. In some embodiments, the palladium compound comprises Pd(OAc) 2 (palladium(II) acetate), Pd(PPh 3 ) 4 (Tetrakis(triphenylphosphine)palladium(0)), PdCl 2 [P(o-Tol) 3 ] 2 (Dichlorobis(tri-o-tolylphosphine)palladium(II)), Pd(dba) 2 (bis(dibenzylideneacetone)palladium(0)), Pd 2 (dba) 3 (tris(dibenzylideneacetone)dipalladium(0)) or Pd(dppf)Cl 2 ([1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)). In some embodiments, the palladium compound comprises Pd(OAc) 2 .

[0181] In some embodiments, the ligand is Xantphos, diphenylphosphinobinaphthyl (BINAP), diphenylphosphinoferrocene (DPPF), tri(o-tolyl)phosphine, (wherein "Cy" is cyclohexyl) or any palladium cross-coupling ligand known to those of ordinary skill in the art, not limited to those described in Hartwig, JF (2008), "Evolution of a Fourth Generation Catalyst for the Amination and Thioetherification of Aryl Halides", Acc. Chem. Res., 41 (11): 1534-1544 and Surry, DS; Buchwald, SL (2008), "Biaryl Phosphane Ligands in Palladiu m-Catalyzed Amination", Angew. Chem. Int. Ed., 47 (34): 6338-6361, the disclosures of which are hereby incorporated by reference in their entirety. In some embodiments, the ligand is Xantphos. Xantphos has the formula:

[0182] Wherein "Ph" is phenyl.

[0183] In some embodiments, the method further comprises contacting the palladium compound, the ligand, compound 4 and / or the compound of formula II or II' with a salt. In some embodiments, the salt is NaOt-Bu, LiHMDS, KOH, K 2 CO 3 , NaOH, Cs 2 CO 3 or any other salt described in the publications mentioned above, Hartwig et al. or Surrey et al. In some embodiments, the salt is K 2 CO 3 .

[0184] In certain embodiments, the palladium-catalyzed cross-coupling comprises reacting Pd(OAc) in a suitable organic solvent. 2 、Xantphos、K 2 CO 3 , compound 4 and a compound of formula II or II' are contacted. In some embodiments, the solvent includes DME (1,2-dimethoxyethane). In certain embodiments, the compound of formula I or I' (cross-coupling product) is washed with N-Ac-L-cysteine ​​(NAC).

[0185] In certain embodiments, the method further comprises distilling the NAC washed compound of formula I or I', dissolving in an organic solvent (i.e., THF) described below and contacting with activated carbon. In certain embodiments, the compound of formula I or I' and activated carbon are heated. In certain embodiments, the heating is to a temperature between about 40°C to about 50°C, about 50°C to about 60°C, about 60°C to about 70°C, or about 70°C to about 80°C.

[0186] In certain embodiments, the compound of formula I or I' is contacted with activated carbon. In certain embodiments, the compound of formula I or I' is contacted with 3-mercaptopropylethyl sulfide silica (SPM32). The contact may be carried out after contact with activated carbon. In certain embodiments, the compound of formula I or I' and activated carbon are heated during contact. In certain embodiments, the temperature is heated to about 40°C to about 50°C, about 50°C to about 60°C, about 60°C to about 70°C, or about 70°C to about 80°C. In certain embodiments, the compound of formula I or I' is ground after SPM32 contact. It can be ground by one or more solvents described below. In certain embodiments, the compound of formula I or I' is ground by methyl tert-butyl ether (MTBE). In certain embodiments, grinding includes heating to a temperature between about 40°C to about 50°C, about 50°C to about 60°C, about 60°C to about 70°C, or about 70°C to about 80°C. In certain embodiments, milling further comprises cooling the heated compound of Formula I or I' to a temperature between about 0°C to about 10°C, about 10°C to about 20°C, or about 20°C to about 30°C.

[0187] In certain embodiments, the cross-coupled compound of Formula I or I' is dissolved in a suitable organic solvent before and / or after contacting with charcoal or SPM32; ie, those solvents described below. In some embodiments, the solvent is DCM (dichloromethane).

[0188] The cross-coupling techniques, palladium compounds, ligands and salts described above may be modified as known in the art, for example by using the techniques described in Palladium-Catalyzed Coupling Reactions, A. Molnár, 1st edition, Wiley-VCH, 2013, the entire contents of each of which are incorporated herein by reference.

[0189] In certain embodiments, the method comprises:

[0190] a) the compound of formula III:

[0191]

[0192] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; using compound 5:

[0193]

[0194] or a pharmaceutically acceptable salt thereof;

[0195] To produce a compound of formula II;

[0196] b) making the compound of formula II:

[0197]

[0198] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; and compound 4:

[0199]

[0200]

[0201] or a pharmaceutically acceptable salt thereof to produce a compound of formula I; and c) making the compound of formula I:

[0202]

[0203] or a pharmaceutically acceptable salt thereof.

[0204] In certain embodiments, the compound of Formula III is Compound 7:

[0205]

[0206] In certain embodiments, the method comprises:

[0207] d) the compound of formula III:

[0208]

[0209]

[0210] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; using compound 5':

[0211]

[0212] or a pharmaceutically acceptable salt thereof;

[0213] To produce a compound of formula II';

[0214] e) making the compound of formula II':

[0215]

[0216] or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; and compound 4:

[0217]

[0218] or a pharmaceutically acceptable salt thereof to produce a compound of formula I'; and

[0219] f) making the compound of formula I':

[0220]

[0221] or a pharmaceutically acceptable salt thereof.

[0222] In certain embodiments, the compound of Formula III is Compound 7:

[0223]

[0224] In some embodiments, the compound of formula II or II' is ground by an alkane after amidation. The grinding can be performed before the subsequent cross-coupling. The alkane can be selected from butane, pentane, hexane, heptane, octane, nonane, decane or a mixture thereof. In some embodiments, the compound of formula II or II' is ground by heptane after amidation. In some embodiments, the compound of formula II or II' is ground by n-heptane after amidation. In some embodiments, the compound of formula II or II' is ground by n-heptane after amidation, wherein the heptane is at a temperature between about 16°C to about 18°C, about 18°C ​​to about 20°C, about 20°C to about 22°C or about 22°C to about 24°C.

[0225] It is known to those of ordinary skill in the art that amidation includes hydrolysis of carboxylic acid and amine to form an amide bond. In certain embodiments, amidation includes treating a compound of formula III and compound 5 or 5' with a base. In some embodiments, the base includes diisopropylethylamine (DIPEA), triethylamine (TEA) or pyridine. In some embodiments, the base includes DIPEA. In some embodiments, amidation also includes contacting T3P (propylphosphonic anhydride) with a compound of formula III, compound 5 or 5' and a base. In some embodiments, amidation is pure. In some embodiments, amidation is carried out in a solvent (i.e., DCM) described below.

[0226] In some embodiments, the amidation is carried out at a temperature of about -10°C to about -5°C, about -5°C to about 0°C, about 0°C to about 5°C, about 5°C to about 10°C, or at about room temperature (22°C).

[0227] Synthesis of intermediates

[0228] In another aspect, a process for preparing a compound of formula I is described:

[0229]

[0230] wherein PG is a suitable amino protecting group, the method comprises treating a compound of formula II:

[0231]

[0232] or a pharmaceutically acceptable salt thereof, and compound 4:

[0233]

[0234] or cross-coupled with a pharmaceutically acceptable salt thereof.

[0235] The cross-coupling can be performed using any of the conditions, reagents, ligands, catalysts, salts or additives described above.

[0236] In certain embodiments, the method comprises:

[0237] a) the compound of formula III:

[0238]

[0239] or a pharmaceutically acceptable salt thereof, using compound 5:

[0240]

[0241] or a pharmaceutically acceptable salt thereof;

[0242] To produce a compound of formula II; and

[0243] b) making the compound of formula II:

[0244]

[0245] or a pharmaceutically acceptable salt thereof, and compound 4:

[0246]

[0247] or a pharmaceutically acceptable salt thereof,

[0248] To produce the compound of formula I.

[0249] Amidation and / or cross-coupling can be performed using any of the conditions, reagents, or additives described above.

[0250] In another aspect, a method for preparing a compound of formula II is described:

[0251]

[0252] or a pharmaceutically acceptable salt thereof; the method comprising:

[0253]

[0254] or a pharmaceutically acceptable salt thereof, using compound 5:

[0255]

[0256] or a pharmaceutically acceptable salt thereof is amidated; to produce a compound of formula II.

[0257] In another aspect, a process for preparing a compound of formula I' is described:

[0258]

[0259] wherein PG is a suitable amino protecting group, the method comprises treating a compound of formula II':

[0260]

[0261] or a pharmaceutically acceptable salt thereof, and compound 4:

[0262]

[0263] or cross-coupled with a pharmaceutically acceptable salt thereof.

[0264] The cross-coupling can be performed using any of the conditions, reagents, ligands, catalysts, salts or additives described above.

[0265] In certain embodiments, the method comprises:

[0266] c) treating a compound of formula III:

[0267]

[0268] or a pharmaceutically acceptable salt thereof, using compound 5':

[0269]

[0270] or a pharmaceutically acceptable salt thereof;

[0271] To produce a compound of formula II'; and

[0272] d) making the compound of formula II':

[0273]

[0274] or a pharmaceutically acceptable salt thereof, and compound 4:

[0275]

[0276] or a pharmaceutically acceptable salt thereof,

[0277] to produce the compound of formula I'.

[0278] Amidation and / or cross-coupling can be performed using any of the conditions, reagents, or additives described above.

[0279] In another aspect, a method for preparing a compound of formula II' is described:

[0280]

[0281] or a pharmaceutically acceptable salt thereof; the method comprising:

[0282]

[0283] or a pharmaceutically acceptable salt thereof, using compound 5':

[0284]

[0285] or a pharmaceutically acceptable salt thereof is amidated; to produce a compound of formula II'.

[0286] Amidation can be performed using any of the conditions, reagents, or additives described above.

[0287] In some embodiments, the compound of formula II or II' is triturated with heptane after amidation. In some embodiments, the compound of formula II or II' is triturated with n-heptane after amidation. In some embodiments, the compound of formula II or II' is triturated with n-heptane after amidation, wherein the heptane is at a temperature between about 16°C to about 18°C, about 18°C ​​to about 20°C, about 20°C to about 22°C, or about 22°C to about 24°C.

[0288] In certain embodiments, the amidation comprises treating the compound of formula III and compound 5 or 5' with a base. In some embodiments, the base comprises diisopropylethylamine (DIPEA), triethylamine (TEA) or pyridine. In some embodiments, the base comprises DIPEA. Amidation and cross-coupling can be performed using any of the conditions, reagents or additives described above.

[0289] In any of the above-mentioned preparation methods, the reaction can be carried out neat or in a solvent. Suitable media are solvents or solvent mixtures, which, in combination with the combined compounds, can promote the progress of the reaction between them. Suitable solvents can dissolve one or more reaction components, or, alternatively, suitable solvents can promote the stirring of a suspension of one or more reaction components. Examples of suitable solvents are protic solvents, halogenated hydrocarbons, ethers, esters, aromatic hydrocarbons, polar or non-polar aprotic solvents, or any mixture thereof. Such mixtures include, for example, mixtures of protic solvents and aprotic solvents, such as benzene / methanol / water; benzene / water; DME / water, etc.

[0290] These and other such suitable solvents are well known in the art, see, for example, "Advanced Organic Chemistry", Jerry March, 5th Edition, John Wiley and Sons, NY, interchangeably.

[0291] Use, preparation and administration

[0292] Pharmaceutically acceptable compositions

[0293] According to another embodiment, a composition is provided, comprising a compound produced by the method herein and a pharmaceutically acceptable carrier, adjuvant or vehicle. The amount of the compound in the composition is effective to measurably inhibit TYK2 protein kinase or its mutant in a biological sample or in a patient. In certain embodiments, the amount of the compound in the composition is effective to measurably inhibit TYK2 protein kinase or its mutant in a biological sample or in a patient. In certain embodiments, the composition is formulated for administration to a patient in need of such a composition. In some embodiments, the composition is formulated for oral administration to a patient.

[0294] As used herein, the term "patient" means an animal, preferably a mammal, and most preferably a human.

[0295] The term "pharmaceutically acceptable carrier, adjuvant or vehicle" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated therewith. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the composition include, but are not limited to, ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and lanolin.

[0296] "Pharmaceutically acceptable derivative" means any non-toxic salt, ester, ester salt or other derivative of a compound (Compound 1) which, upon administration to a recipient, is capable of providing, directly or indirectly, the compound or its inhibitory active metabolite or residue.

[0297] As used herein, the term "inhibitory active metabolites or residues thereof" means that the metabolites or residues thereof are also inhibitors of TYK2 protein kinase or mutants thereof.

[0298] The composition can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implantable reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally or intravenously. The sterile injectable form of the composition can be an aqueous or oily suspension. These suspensions can be prepared using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. Sterile injectable preparations can also be sterile injectable solutions or suspensions in non-toxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are routinely used as solvents or suspension media.

[0299] For this purpose, any gentle fixed oil can be used, including synthetic monoglycerides or diglycerides. Like pharmaceutically acceptable natural oils (such as olive oil or castor oil, especially in its polyoxyethylated form), fatty acids (such as oleic acid and its glyceride derivatives) can be used to prepare injectables. These oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants, such as carboxymethyl cellulose or similar dispersants that are commonly used to prepare pharmaceutically acceptable dosage forms including emulsions and suspensions. For the purpose of preparation, other commonly used surfactants can also be used, such as Tween, Span and other emulsifiers or bioavailability enhancers that are commonly used to make pharmaceutically acceptable solids, liquids or other dosage forms.

[0300] Pharmaceutically acceptable pharmaceutical compositions can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also usually added. For oral administration in capsule form, useful diluents include lactose and dry corn starch. When oral use requires an aqueous suspension, the active ingredient is combined with an emulsifier and a suspending agent. If desired, certain sweeteners, flavorings or coloring agents may also be added.

[0301] Alternatively, pharmaceutically acceptable compositions can be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[0302] Pharmaceutically acceptable compositions may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, skin, or lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0303] Topical application to the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.Topical transdermal patches may also be used.

[0304] For topical application, the pharmaceutically acceptable composition provided can be formulated in a suitable ointment containing an active component suspended or dissolved in one or more carriers. Carriers for topical application of Compound 1 include, but are not limited to, mineral oil, liquid vaseline, white vaseline, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. Alternatively, the pharmaceutically acceptable composition provided can be formulated in a suitable lotion or cream containing an active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0305] For ophthalmic use, provided pharmaceutically acceptable compositions can be formulated as micronized suspensions in isotonic, pH-adjusted sterile saline, or preferably as solutions in isotonic, pH-adjusted sterile saline, with or without preservatives such as benzalkonium chloride. Alternatively, for ophthalmic use, pharmaceutically acceptable compositions can be formulated in ointments such as petrolatum.

[0306] Pharmaceutically acceptable compositions may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters (for enhanced bioavailability), fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0307] Most preferably, the pharmaceutically acceptable composition is formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharmaceutically acceptable composition is not administered with food. In other embodiments, the pharmaceutically acceptable composition is administered with food.

[0308] The amount of the compound that can be combined with the carrier materials to produce a single dosage form of the composition will vary depending upon the host being treated, the particular mode of administration. Preferably, the provided compositions should be formulated so that a dosage of 0.01-100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.

[0309] It will also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of Compound 1 employed, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination and the judgment of the treating physician, as well as the severity of the particular disease being treated.

[0310] Uses of compounds and pharmaceutically acceptable compositions

[0311] Compound 1 and compositions described herein are generally useful for inhibiting the kinase activity of one or more enzymes. In some embodiments, the kinase inhibited by Compound 1 and methods herein is TYK2.

[0312] TYK2 is a non-receptor tyrosine kinase member of the Janus kinase (JAK) protein kinase family. The mammalian JAK family consists of four members: TYK2, JAK1, JAK2 and JAK3. JAK proteins (including TYK2) are essential for cytokine signaling. TYK2 associates with the cytoplasmic domains of type I and type II cytokine receptors and interferon type I and type III receptors, and is activated by those receptors when cytokines bind. Cytokines involved in TYK2 activation include interferons (e.g., IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ (also known as limitin)) and interleukins (e.g., IL-4, IL-6, IL-10, IL-11, IL-12, IL-13, IL-22, IL-23, IL-27, IL-31, oncostatin M, ciliary neurotrophic factor, cardiotrophin 1, cardiotrophin-like cytokine, and LIF).Velasquez et al., "Aprotein kinase in the interferonα / β signaling pathway", Cell (1992) 70:313; Stahl et al., "Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6βreceptorcomponents", Science (1994) 263:92; Finbloom et al., "IL-10 induces thetyrosine Phosphorylation of Tyk2 and Jak1 and the differential assembly ofStat1 and Stat3 complexes in human T cells and monocytes", J. Immunol. (1995) 155:1079; Bacon et al., "Interleukin 12(IL-12) induces tyrosine phosphorylation ofJak2 and Tyk2: differential use of Janus family kinases by IL-2and IL-12", J. Exp. Med. (1995) 181: 399; Welham et al., "Interleukin-13 signal transduction in lymphohemopoietic cells: similarities and differences in signal transduction with interleukin-4 and insulin", J. Biol. Chem. (1995) 270: 12286; Parham et al., "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R", J. Immunol. (2002) 168: 5699. Activated TYK2 then goes on to phosphorylate other signaling proteins, such as members of the STAT family, including STAT1, STAT2, STAT4 and STAT6.

[0313] IL-23 activation of TYK2 is associated with inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Duerr et al., "A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene", Science (2006) 314: 1461-1463. TYK2, as a downstream effector of IL-23, is also involved in psoriasis, ankylosing spondylitis, and Behcet's disease ( disease). Cho et al., "Genomics and the multifactorial nature of human auto-immune disease", N.Engl.J.Med(2011) 365:1612-1623; Cortes et al., "Identification of multiple riskvariants for ankylosing spondylitis through high-density genotyping ofimmune-related loci", Nat. Genet. (2013) 45(7):730-738; Remmers et al., "Genome-wide association study identifies var iants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with disease”, Nat. Genet. (2010) 42: 698-702. A genome-wide association study of 2,622 individuals with psoriasis identified an association between disease susceptibility and TYK2. Strange et al., “A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1”, Nat. Genet. (2010) 42: 985-992. Knockout or tyrosine phosphorylation inhibitor inhibition of TYK2 significantly reduced both IL-23 and IL-22-induced dermatitis. Ishizaki et al., “Tyk2 is a therapeutic target for psoriasis-like skin inflammation”, Intl. Immunol. (2013), doi: 10.1093 / intimm / dxt062.

[0314] TYK2 also plays a role in respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and cystic fibrosis. Goblet cell hyperplasia (GCH) and mucus hypersecretion are mediated by IL-13-induced TYK2 activation, which in turn activates STAT6. Zhang et al., "Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2 / STAT6 pathway", FASEB J. (2012) 26: 1-11.

[0315] Reduced TYK2 activity protects joints from collagen antibody-induced arthritis, a model of human rheumatoid arthritis. Mechanistically, reduced Tyk2 activity reduces T h 1 / T h 17 related cytokines and matrix metalloproteinases and other key markers of inflammation. Ishizaki et al., “Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice”, Intl. Immunol. (2011) 23(9): 575-582.

[0316] Compared with controls, TYK2 knockout mice showed complete resistance in experimental autoimmune encephalomyelitis (EAE, an animal model of multiple sclerosis (MS)), with no infiltration of CD4 T cells in the spinal cord, indicating that TYK2 is essential for pathogenic CD4-mediated disease development in MS. Oyamada et al., "Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis", J. Immunol. (2009) 183: 7539-7546. This confirms previous studies linking increased TYK2 expression to MS susceptibility. Ban et al., "Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor", Eur J. Hum. Genet. (2009) 17: 1309-1313. Loss-of-function mutations in TYK2 result in reduced demyelination and increased remyelination of neurons, further suggesting a role for TYK2 inhibitors in the treatment of MS and other CNS demyelinating disorders.

[0317] TYK2 is the only signaling messenger common to both IL-12 and IL-23. TYK2 knockout reduces footpad thickness induced by methylated BSA injection, psoriasis-like skin inflammation induced by imiquimod, and colitis induced by dextran sulfate sodium or 2,4,6-trinitrobenzenesulfonic acid in mice.

[0318] Common links of various type I IFN signaling genes to systemic lupus erythematosus (SLE, an autoimmune disorder) and association studies have shown a strong and significant correlation between loss-of-function mutations in TYK2 and reduced prevalence of SLE in families with affected members. Sigurdsson et al., "Polymorphisms in the Tyrosine Kinase 2 and Interferon Regulatory Factor 5 Genes Are Associated with Systemic Lupis Erythematosus", Am. J. Hum. Genet. (2005) 76: 528-537. A genome-wide association study of individuals with SLE versus an unaffected cohort showed a highly significant association between the TYK2 locus and SLE. Graham et al., “A ssociation of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with SystemicLupus Erythematosus,” PLoS Genetics (2011) 7(10):e1002341.

[0319] TYK2 has been shown to play an important role in maintaining tumor surveillance, and TYK2 knockout mice show impaired cytotoxic T cell responses and accelerated tumor development. However, these effects are associated with effective inhibition of natural killer (NK) and cytotoxic T lymphocytes, indicating that TYK2 inhibitors will be highly suitable for treating autoimmune disorders or transplant rejection. Although other JAK family members (such as JAK3) have similar effects in the immune system, TYK2 is considered an excellent target because it involves fewer and more closely related signal transduction pathways, thereby making off-target effects less. Simma et al., "Identification of an Indispensable Role for Tyrosine Kinase 2in CTL-Mediated Tumor Surveillance", Cancer Res. (2009) 69: 203-211.

[0320] However, in contradiction to the reduced tumor surveillance observed by Simma et al., studies in T-cell acute lymphoblastic leukemia (T-ALL) indicate that T-ALL is highly dependent on IL-10 via STAT1-mediated signal transduction via TYK 2 to maintain cancer cell survival via upregulation of the anti-apoptotic protein BCL2. Knockdown of TYK2, rather than other JAK family members, reduces cell growth. Specific activating mutations of TYK2 that promote cancer cell survival include those of the FERM domain (G36D, S47N, and R425H), the JH2 domain (V731I), and the kinase domain (E957D and R1027H). However, the kinase function of TYK2 has also been identified to be essential for prolonging cancer cell survival, because TYK2 enzymes characterized by kinase-dead mutations (M978Y or M978F) in addition to activating mutations (E957D) lead to transformation failure. Sanda et al., "TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia", CancerDisc. (2013) 3(5):564-577.

[0321] Therefore, selective inhibition of TYK2 has been considered a suitable target for patients with IL-10 and / or BCL2 addicted tumors, such as 70% of adult T-cell leukemia cases. Fontan et al., "Discovering What Makes STATSignaling TYK in T-ALL", Cancer Disc. (2013) 3:494-496.

[0322] It has also been shown that TYK2-mediated STAT3 signaling mediates neuronal cell death caused by amyloid-β (Aβ) peptide. Reduced TYK2 phosphorylation of STAT3 after Aβ administration reduces neuronal cell death, and increased STAT3 phosphorylation is observed in autopsy brains of Alzheimer's patients. Wan et al., "Tyk / STAT3 Signaling Mediates β-Amyloid-Induced Neuronal Cell Death: Implications in Alzheimer's Disease", J. Neurosci. (2010) 30(20): 6873-6881.

[0323] Inhibition of the JAK-STAT signaling pathway has also been associated with hair growth and reversal of hair loss associated with alopecia areata. Xing et al., “Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition”, Nat. Med. (2014) 20: 1043-1049; Harel et al., “Pharmacologic inhibition of JAK-STA T signaling promotes hair growth”, Sci. Adv. (2015) 1(9): e1500973.

[0324] Therefore, compounds that inhibit TYK2 activity are beneficial, especially those that are selective over JAK2.Such compounds should deliver a pharmacological response that advantageously treats one or more of the conditions described herein without the side effects associated with JAK2 inhibition.

[0325] Even though TYK2 inhibitors are known in the art, there continues to be a need to provide novel inhibitors with more effective or advantageous pharmaceutically relevant properties. For example, compounds with increased activity, selectivity over other JAK kinases (particularly JAK2), and ADMET (absorption, distribution, metabolism, excretion, and / or toxicity) properties. Thus, in some embodiments, the Compound 1 inhibitor of TYK2 exhibits selectivity over JAK2.

[0326] The activity of compound 1 used herein as an inhibitor of TYK2 or its mutants can be determined in vitro, in vivo or in a cell line. In vitro assays include assays for the inhibition of phosphorylation activity and / or subsequent functional results or ATPase activity of activated TYK2 or its mutants. Alternative in vitro assays quantify the ability of inhibitors to bind to TYK2. Inhibitor binding can be measured by radiolabeling the inhibitor before binding, isolating the inhibitor / TYK2 complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding can be determined by running a competition experiment in which a new inhibitor is incubated with TYK2 bound to a known radioligand. Representative in vitro and in vivo assays that can be used to determine TYK2 inhibitors include those described and disclosed in the publication, for example, each of which is incorporated herein by reference in its entirety.

[0327] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset or inhibiting the progression of a disease or disorder as described herein or one or more symptoms thereof. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., in view of a history of symptoms and / or in view of genetic or other susceptibility factors). Treatment may also be continued after the symptoms subside, for example, to prevent or delay their recurrence.

[0328] Compound 1 is an inhibitor of TYK2 and is therefore useful for treating one or more conditions associated with the activity of TYK2 or a mutant thereof. Thus, in certain embodiments, a method for treating a TYK2-mediated condition comprises the step of administering to a patient in need thereof Compound 1 or a pharmaceutically acceptable composition thereof produced by the methods described herein.

[0329] As used herein, the term "TYK2-mediated" disorder, disease and / or condition as used herein means any disease or other deleterious condition in which TYK2 or a mutant thereof is known to play a role. Thus, another embodiment is directed to treating or lessening the severity of one or more diseases in which TYK2 or a mutant thereof is known to play a role. Such TYK2-mediated disorders include, but are not limited to, autoimmune disorders, inflammatory disorders, proliferative disorders, endocrine disorders, neurological disorders, and transplantation-related disorders.

[0330] In some embodiments, a method for treating one or more disorders, wherein the disorder is selected from an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, and a transplantation-related disorder, comprises administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of Compound 1 produced by the methods herein, or a pharmaceutically acceptable salt thereof.

[0331] In some embodiments, the disorder is an autoimmune disorder. In some embodiments, the disorder is selected from type 1 diabetes, cutaneous lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, psoriasis, Behcet's disease, POEMS syndrome, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.

[0332] In some embodiments, the disorder is an inflammatory disorder. In some embodiments, the inflammatory disorder is rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, hepatomegaly, Crohn's disease, ulcerative colitis, inflammatory bowel disease.

[0333] In some embodiments, the disorder is a proliferative disorder. In some embodiments, the proliferative disorder is a blood cancer. In some embodiments, the proliferative disorder is a leukemia. In some embodiments, the leukemia is a T-cell leukemia. In some embodiments, the T-cell leukemia is T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the proliferative disorder is polycythemia vera, myelofibrosis, or essential thrombocythemia.

[0334] In some embodiments, the disorder is an endocrine disorder. In some embodiments, the endocrine disorder is polycystic ovary syndrome, Crouzon's syndrome, or type 1 diabetes.

[0335] In some embodiments, the disorder is a neurological disorder. In some embodiments, the neurological disorder is Alzheimer's disease.

[0336] In some embodiments, the proliferative disorder is associated with one or more activating mutations in TYK2. In some embodiments, the activating mutation in TYK2 is a mutation in the FERM domain, the JH2 domain, or the kinase domain. In some embodiments, the activating mutation in TYK2 is selected from G36D, S47N, R425H, V731I, E957D, and R1027H.

[0337] In some embodiments, the disorder is associated with transplantation. In some embodiments, the disorder associated with transplantation is transplant rejection or graft-versus-host disease.

[0338] In some embodiments, the disorder is associated with type I interferon, IL-10, IL-12, or IL-23 signaling. In some embodiments, the disorder is associated with type I interferon signaling. In some embodiments, the disorder is associated with IL-10 signaling. In some embodiments, the disorder is associated with IL-12 signaling. In some embodiments, the disorder is associated with IL-23 signaling.

[0339] Compound 1 prepared by the methods herein can also be used to treat inflammatory or allergic conditions of the skin, such as psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, allergic vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, cutaneous lupus erythematosus, systemic lupus erythematosus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, acquired epidermolysis bullosa, acne vulgaris, and other inflammatory or allergic conditions of the skin.

[0340] Compound 1 produced by the methods herein can also be used to treat other diseases or conditions, such as diseases or conditions with an inflammatory component, for example, to treat diseases and conditions of the eye (such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis), diseases affecting the nose (including allergic rhinitis), and inflammatory diseases involving autoimmune reactions or having an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), cutaneous lupus erythematosus, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome (Steven-Johnson syndrome), and other diseases. syndrome), idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine eye diseases, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary sclerosis, uveitis (anterior and posterior), Sjogren's syndrome, keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, cryptopyrin-associated periodic syndromes, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis (with and without nephrotic syndrome,Examples include idiopathic nephrotic syndrome or minimal change disease), chronic granulomatous disease, endometriosis, leptospirosis nephropathy, glaucoma, retinal disease, aging, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscular dystrophy, cataract, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, antihidrotic ectodermal dysplasia, Behçet's disease, incontinence pigmenti, Paget's disease disease), pancreatitis, hereditary periodic fever syndrome, asthma (allergic and non-allergic, mild, moderate, severe, bronchitis, and exercise-induced asthma), acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivity reactions, anaphylaxis, sinusitis, eye allergies, silica-induced disease, COPD (damage, airway inflammation, bronchial hyperresponsiveness, remodeling, or decreased disease progression), lung disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation combined with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease disease), lichen planus, type 1 or type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergies, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henoch-Schonlein purpura purpura), hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, eustachian tube inflammation, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis.

[0341] In some embodiments, the inflammatory disease treatable according to the method is selected from acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic juvenile idiopathic arthritis (SJIA), cryptopyrin-associated periodic syndrome (CAPS), and osteoarthritis.

[0342] In some embodiments, the inflammatory disease treatable according to the methods is T h 1 or T h17-mediated diseases. In some embodiments, T h The 17-mediated disease is selected from the group consisting of cutaneous lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease (including Crohn's disease or ulcerative colitis).

[0343] In some embodiments, the inflammatory disease treatable according to the method is selected from Sjögren's syndrome, allergic disorders, osteoarthritis, eye disorders such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, and diseases affecting the nose such as allergic rhinitis.

[0344] Furthermore, described herein is the use of Compound 1, or a pharmaceutically acceptable salt, or hydrate or solvate thereof, as defined herein, for the preparation of a medicament for the treatment of an autoimmune, inflammatory or proliferative disorder or a disorder generally associated with transplantation.

[0345] Combination therapy

[0346] Depending on the specific condition or disease to be treated, other therapeutic agents that are normally administered to treat that condition may be administered in combination with Compound 1 and compositions produced by the methods herein. As used herein, other therapeutic agents that are normally administered to treat a particular disease or condition are referred to as "appropriate for the disease or condition being treated."

[0347] In certain embodiments, provided combinations or compositions thereof are administered in combination with another therapeutic agent.

[0348] Examples of agents with which the combination may also be combined include, but are not limited to: treatments for Alzheimer's disease, such as and Treatments for HIV, such as ritonavir; treatments for Parkinson's Disease, such as L-DOPA / carbidopa, entacapone, ropinirole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating multiple sclerosis (MS), such as beta interferon (e.g. and ), and mitoxantrone; for asthma treatments such as albuterol and Agents used to treat schizophrenia, such as Zyprexa, Risperdal, Seroquel, and Haloperidol; anti-inflammatory agents, such as corticosteroids, TNF blockers, IL-1RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulators and immunosuppressants, such as cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, and tacrolimus. mofetil), interferon, corticosteroids, cyclophosphamide, azathioprine and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferon, anticonvulsants, ion channel blockers, riluzole and anti-Parkinson's disease agents; agents for treating cardiovascular diseases such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers and statins; agents for treating liver diseases such as corticosteroids, cholestyramine, interferon and antiviral agents; agents for treating blood disorders such as corticosteroids, anti-leukemia agents and growth factors; agents that prolong or improve pharmacokinetics such as cytochrome P450 inhibitors (i.e., metabolic destruction inhibitors) and CYP3A4 inhibitors (e.g., ketoconazole and ritonavir); and agents for treating immunodeficiency disorders such as gamma globulin.

[0349] In certain embodiments, the combination therapy, or a pharmaceutically acceptable composition thereof, is administered in combination with a monoclonal antibody or siRNA therapeutic.

[0350] Those other agents may be administered separately from the provided combination therapies as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with the compound in a single composition. If administered as part of a multiple dosage regimen, the two active agents may be presented simultaneously, sequentially, or within a certain time period of each other, typically within five hours of each other.

[0351] As used herein, the terms "combination", "combined" and related terms refer to the simultaneous or sequential administration of therapeutic agents. For example, the combination can be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms or together in a single unit dosage form.

[0352] The amount of the other therapeutic agent present in the composition will not exceed the amount normally administered in a composition comprising the therapeutic agent as the only active agent. Preferably, the amount of the other therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount normally present in a composition comprising the agent as the only therapeutically active agent.

[0353] In one embodiment, compositions comprising compound 1 and one or more other therapeutic agents are contemplated. The therapeutic agent may be administered together with compound 1, or may be administered before or after compound 1 is administered. Suitable therapeutic agents are further described in detail below. In certain embodiments, compound 1 may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours before the therapeutic agent. In other embodiments, compound 1 may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours after the therapeutic agent.

[0354] In another embodiment, a method of treating an inflammatory disease, disorder or condition by administering Compound 1 and one or more other therapeutic agents to a patient in need thereof is described. Such other therapeutic agents may be small molecules or recombinant biologics and include, for example, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), colchicine Corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, etc.), probenecid, allopurinol, febuxostat Sulfasalazine Antimalarial drugs (such as hydroxychloroquine) and chloroquine ), methotrexate Gold salts (such as gold thioglucosidase gold thiomalate and auranofin )、D-penicillamine or ), Azathioprine Cyclophosphamide Chlorambucil Cyclosporine Leflunomide and “anti-TNF” agents (such as etanercept Infliximab Golimumab Certolizumab pegol and adalimumab ), "anti-IL-1" agents (such as anakinra and rilonacept ), canakinumab Anti-Jak inhibitors (such as tofacitinib), antibodies (such as rituximab ), "anti-T cell" agents (such as abatacept ), "anti-IL-6" agents (such as tocilizumab) ), diclofenac, cortisone, hyaluronic acid ( or ), monoclonal antibodies (such as tanezumab), anticoagulants (such as heparin ( or ) and warfarin ), antidiarrheal drugs (such as diphenoxylate) and loperamide ), bile acid binders (such as cholestyramine), alosetron Lubiprostone Laxatives (such as Milk of Magnesia, polyethylene glycol Corr and ), anticholinergics or antispasmodics (such as dicyclomine) ), beta-2 agonists (such as albuterol ( HFA, HFA), levosalbutamol Metaproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium ), inhaled corticosteroids (such as beclomethasone dipropionate) and ), triamcinolone acetonide Mometasone Budesonide and flunisolide ), Cromolyn sodium Methylxanthines (such as theophylline) and aminophylline), IgE antibodies (such as omalizumab) ), nucleoside reverse transcriptase inhibitors (such as zidovudine) Abacavir Abacavir / lamivudine Abacavir / Lamivudine / Zidovudine Didanosine Emtricitabine Lamivudine Lamivudine / zidovudine Stavudine and zalcitabine ), non-nucleoside reverse transcriptase inhibitors (such as delavirdine) Efavirenz Nevairapine and etravirine ), nucleotide reverse transcriptase inhibitors (such as tenofovir ), protease inhibitors (such as amprenavir) Atazanavir Darunavir Fosamprenavir Indinavir Lopinavir and ritonavir ), nelfinavir Ritonavir Saquinavir (Fo or ) and tipranavir Entry inhibitors (such as enfuvirtide and maraviroc ), integrase inhibitors (such as raltegravir) Doxorubicin Vincristine Bortezomib and dexamethasone With lenalidomide ) or any combination thereof.

[0355] In another embodiment, a method of treating rheumatoid arthritis is described, comprising administering to a patient in need thereof Compound 1 and one or more other therapeutic agents selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac and celecoxib), corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, etc.), sulfasalazine Antimalarial drugs (such as hydroxychloroquine) and chloroquine ), methotrexate Gold salts (such as gold thioglucosidase gold thiomalate Auranofin )、D-Penicillamine( or ), Azathioprine Cyclophosphamide Chlorambucil Cyclosporine Leflunomide and “anti-TNF” agents (such as etanercept Infliximab Golimumab Certolizumab Adalimumab ), "anti-IL-1" agents (such as anakinra and linacept ), antibodies (such as rituximab ), "anti-T cell" agents (such as abatacept ) and “anti-IL-6” agents (such as tocilizumab ).

[0356] In some embodiments, a method of treating osteoarthritis is described, comprising administering to a patient in need thereof Compound 1 and one or more other therapeutic agents selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac and celecoxib), diclofenac, cortisone, hyaluronic acid ( or ) and monoclonal antibodies (such as tanezumab).

[0357] In some embodiments, a method of treating cutaneous lupus erythematosus or systemic lupus erythematosus is described, the method comprising administering to a patient in need thereof Compound 1 and one or more other therapeutic agents selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac and celecoxib), corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, etc.), antimalarials (such as hydroxychloroquine and chloroquine ), cyclophosphamide Methotrexate Azathioprine and anticoagulants (such as heparin ( or ) and warfarin ).

[0358] In some embodiments, a method of treating Crohn's disease, ulcerative colitis, or inflammatory bowel disease is described, the method comprising administering to a patient in need thereof Compound 1 and one or more additional therapeutic agents selected from the group consisting of mesalamine Sulfasalazine Antidiarrheal drugs (such as diphenoxylate and loperamide ), bile acid binders (such as cholestyramine), alosetron Lubiprostone Laxatives (such as milk of magnesia, polyethylene glycol and ) and anticholinergics or antispasmodics (such as dicyclomine ), anti-TNF therapy, steroids, and antibiotics such as metronidazole (Flagyl) or ciprofloxacin.

[0359] In some embodiments, a method of treating asthma is described, comprising administering to a patient in need thereof Compound 1 and one or more additional therapeutic agents selected from the group consisting of: Beta-2 agonists (such as albuterol ( HFA, HFA), levosalbutamol Iproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol Xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium ), inhaled corticosteroids (such as prednisone, prednisolone, beclomethasone dipropionate ( and ), triamcinolone acetonide Mometasone Budesonide Flunisolide and ), Sodium Cromolyn Methylxanthines (such as theophylline and aminophylline) and IgE antibodies (such as omalizumab ).

[0360] In some embodiments, methods of treating COPD are described, comprising administering to a patient in need thereof Compound 1 and one or more additional therapeutic agents selected from the group consisting of: a β-2 agonist (such as albuterol ( HFA, HFA), levosalbutamol Iproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol Xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium ), methylxanthines (such as theophylline and aminophylline), inhaled corticosteroids (such as prednisone, prednisolone, beclomethasone dipropionate ( and ), triamcinolone acetonide Mometasone Budesonide Flunisolide and ).

[0361] In another embodiment, a method of treating a hematological malignancy is described, the method comprising administering to a patient in need thereof Compound 1 and one or more additional therapeutic agents selected from the group consisting of: Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, PI3K inhibitors, SYK inhibitors, and combinations thereof.

[0362] In another embodiment, a method of treating a solid tumor is described, the method comprising administering to a patient in need thereof Compound 1 and one or more additional therapeutic agents selected from the group consisting of: Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, PI3K inhibitors, SYK inhibitors, and combinations thereof.

[0363] In another embodiment, a method of treating a hematological malignancy is described, comprising administering Compound 1 and a Hedgehog (Hh) signaling pathway inhibitor to a patient in need thereof. In some embodiments, the hematological malignancy is DLBCL (Ramirez et al., "Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma" Leuk. Res. (2012), published online on July 17, and incorporated herein by reference in its entirety).

[0364] In another embodiment, a method of treating diffuse large B-cell lymphoma (DLBCL) is described, comprising administering to a patient in need thereof Compound 1 and one or more additional therapeutic agents selected from the group consisting of: Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, and combinations thereof.

[0365] In another embodiment, a method of treating multiple myeloma is described, comprising administering to a patient in need thereof Compound 1 and one or more additional therapeutic agents selected from the group consisting of: bortezomib and dexamethasone Hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, TYK2 inhibitors, PI3K inhibitors, SYK inhibitors and lenalidomide combination.

[0366] In another embodiment, a method of treating or lessening the severity of a disease is described, comprising administering Compound 1 and a BTK inhibitor to a patient in need thereof, wherein the disease is selected from inflammatory bowel disease, arthritis, cutaneous lupus erythematosus, systemic lupus erythematosus (SLE), vasculitis, idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, autoimmune thyroiditis, Sjögren's syndrome, multiple sclerosis, systemic sclerosis, neurological Lyme disease, and inflammatory bowel disease. neuroborreliosis), Guillain-Barre syndrome, acute diffuse encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, autoimmune gastritis, pernicious anemia, celiac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary sclerosis, Reiter's syndrome, Takayasu's arteritisarteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, generalized alopecia, Behcet's disease, chronic fatigue, dysautonomia, membranous glomerulonephropathy, endometriosis, interstitial cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia, scleroderma, vulvodynia, hyperproliferative disorders, rejection of transplanted organs or tissues, acquired immunodeficiency syndrome (AIDS, also known as HIV), type 1 diabetes, graft-versus-host disease, transplantation , blood transfusion, anaphylactic reaction, allergy (e.g. to plant pollens, latex, drugs, foods, insect toxins, animal hair, animal dander, dust mites or cockroach calyx), type I allergy, allergic conjunctivitis, allergic rhinitis and atopic dermatitis, asthma, appendicitis, atopic dermatitis, asthma, allergies, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, heart disease Endometritis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henlein-Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonia, polymyositis , proctitis, prostatitis, pyelonephritis, rhinitis, eustachian tube inflammation, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis or vulvitis, B-cell proliferative disorders (e.g., diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, multiple myeloma (also known as plasma cell myeloma), non-Hodgkin's lymphoma (non-Hodgkin'slymphoma, Hodgkin's lymphoma, plasmacytoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma / leukemia or lymphomatoid granulomatosis), breast cancer, prostate cancer, or mast cell cancer (e.g., mastocytoma, mast cell leukemia, mast cell sarcoma, systemic mastocytosis), bone cancer, colorectal cancer, pancreatic cancer, bone and joint diseases (including but not limited to rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis, and Reiter's disease), disease), systemic sclerosis, osteoporosis, bone cancer, bone metastasis), thromboembolic disorders (e.g., myocardial infarction, angina, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transient ischemia, peripheral arterial occlusive disorder, pulmonary embolism, deep vein thrombosis), inflammatory pelvic disease, urethritis, sunburn, sinusitis, pneumonia, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholecystitis, agammaglobulinemia, psoriasis, allergies, Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjogren's disease disease), tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, atherosclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, cutaneous lupus erythematosus, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, scleroderma, mycosis fungoides, and acute inflammatory reactions (such as acute respiratory distress syndrome and ischemia / reperfusion injury).

[0367] In another embodiment, a method of treating or lessening the severity of a disease is described, the method comprising administering Compound 1 prepared according to the methods disclosed herein and a PI3K inhibitor to a patient in need thereof, wherein the disease is selected from cancer, neurodegenerative disorders, angiogenic disorders, viral diseases, autoimmune diseases, inflammatory disorders, hormone-related diseases, disorders associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, disorders associated with cell death, thrombin-induced platelet aggregation, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), liver disease, pathological immune disorders involving T cell activation, cardiovascular disorders, and CNS disorders.

[0368] In another embodiment, a method of treating or lessening the severity of a disease is described, comprising administering Compound 1 prepared according to the methods disclosed herein and a PI3K inhibitor to a patient in need thereof, wherein the disease is selected from a benign or malignant tumor, cancer or solid tumor of the brain, kidney (e.g., renal cell carcinoma (RCC)), liver, adrenal gland, bladder, breast, stomach, gastric tumor, ovary, colon, rectum, prostate, pancreas, lung, vagina, endometrium, cervix, testis, urogenital tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastoma The invention may include, but is not limited to, leukemia, leukemia, leukemia of the head and neck, leukemia of the ovary, leukemia of the scrotum, leukemia of the umbilical cord ... syndrome) or abnormal activation of the PI3K / PKB pathway, asthma of any type or origin (including both intrinsic (non-allergic) asthma and non-intrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitis asthma, exercise-induced asthma, occupational asthma and asthma induced after bacterial infection), acute lung injury (ALI), adult / acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airway or lung disease (COPD, COAD or COLD) (including chronic bronchitis or dyspnea associated therewith, emphysema) and exacerbation of airway hypersensitivity with other drug therapy (particularly other inhaled drug therapy), bronchitis of any type or origin (including but not limited to acute, arachidic, catarrhal, croupus, chronic or tuberculous bronchitis), pneumoconiosis of any type or origin (an inflammatory, usually occupational lung disease,The most common inflammatory diseases are eosinophilic pneumonia, eosinophilic pneumonia, parasitic (particularly metazoan) infections (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), and polyarteritis nodosa. syndrome), eosinophilic granulomas and eosinophil-related disorders affecting the airways triggered by drug-reactions, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, allergic vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphigus, acquired epidermolysis bullosa, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, disorders affecting the nose (including allergic rhinitis), and inflammatory disorders involving autoimmune reactions or having an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), cutaneous lupus erythematosus, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener's granulomatosis, Dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), endocrine eye diseases, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary sclerosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, and glomerulonephritis (with and without nephrotic syndrome, including, for example, idiopathic nephrotic syndrome or minimal change disease), restenosis, cardiomegaly, atherosclerosis, myocardial infarction, ischemic stroke and congestive heart failure, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease disease) and cerebral ischemia, as well as neurodegenerative diseases caused by traumatic injury, glutamate neurotoxicity, and hypoxia.

[0369] In some embodiments, a method of treating a disease or reducing its severity is described, the method comprising administering to a patient in need thereof a compound 1 prepared according to the methods disclosed herein and a Bcl-2 inhibitor, wherein the disease is an inflammatory disorder, an autoimmune disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder. In some embodiments, the disorder is a proliferative disorder, lupus, or lupus nephritis. In some embodiments, the proliferative disorder is chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Hodgkin's disease, small cell lung cancer, non-small cell lung cancer, myelodysplastic syndrome, lymphoma, hematological neoplasm, or solid tumor.

[0370] In some embodiments, a method for treating a disease or reducing its severity is described, the method comprising administering a TYK2 pseudokinase (JH2) domain binding compound and a TYK2 kinase (JH1) domain binding compound to a patient in need thereof. In some embodiments, the disease is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation. In some embodiments, the JH2 domain binds to compound 1 prepared according to the methods disclosed herein. Other suitable JH2 domain binding compounds include those described in WO2014074660A1, WO2014074661A1, WO2015089143A1, and the entire contents of each of the applications are incorporated herein by reference. Suitable JH1 domain binding compounds include those described in WO2015131080A1, and the entire contents of the applications are incorporated herein by reference.

[0371] According to the methods described herein, Compound 1 and compositions can be administered using any amount and any route of administration, and are effective for treating autoimmune disorders, inflammatory disorders, proliferative disorders, endocrine disorders, neurological disorders, or disorders associated with transplantation or reducing their severity. The exact amount required will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the infection, the specific agent, its mode of administration, etc. The compounds herein are preferably formulated in dosage unit form for ease of administration and uniform dosage. As used herein, the expression "dosage unit form" refers to a physically discrete unit of an agent suitable for a patient to be treated. However, it should be understood that the total daily dosage of the compounds and compositions will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient or organism will depend on a variety of factors, including the condition being treated and the severity of the condition; the activity of the specific compound employed; the specific composition employed; the age, weight, general health, sex and diet of the patient; the time of administration, route of administration and rate of excretion of the specific compound employed; the duration of treatment; drugs used in combination or incidentally with the specific compound employed and similar factors well known in the medical art. As used herein, the term "patient" means an animal, preferably a mammal, and most preferably a human.

[0372] Pharmaceutically acceptable compositions can be administered to humans and other animals orally, rectally, parenterally, intracisternal, intravaginal, intraperitoneally, topically (e.g., by powders, ointments, or drops), buccally, as an oral or nasal spray, etc., depending on the severity of the infection being treated. In certain embodiments, the compound can be administered orally or parenterally at a dosage level of about 0.01 mg / kg to about 50 mg / kg, and preferably about 1 mg / kg to about 25 mg / kg of subject body weight per day, once or more a day to obtain the desired therapeutic effect.

[0373] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may also contain inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and aromatics.

[0374] Injectable preparations (e.g., sterile injectable aqueous or oily suspensions) can be prepared using suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used are especially water, Ringer's solution, USP and isotonic sodium chloride solution. In addition, sterile fixed oils are routinely used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectables.

[0375] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0376] To prolong the effect of compound 1, it may be desirable to slow down the absorption of the compound from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material with poor water solubility. The absorption rate of the compound depends on its dissolution rate, and the dissolution rate can then depend on the crystal size and crystalline form. Alternatively, delayed absorption of the compound form administered parenterally is achieved by dissolving or suspending the compound in an oily vehicle. Injectable depot forms are prepared by forming a microcapsule matrix of the compound in a biodegradable polymer (such as polylactide-polyglycolide). Depending on the ratio of the compound to the polymer and the properties of the specific polymer used, the rate of release of compound 1 can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable preparations are also prepared by embedding the compound in a liposome or microemulsion compatible with body tissues.

[0377] Compositions for rectal or vaginal administration are preferably suppositories, which can be prepared by mixing Compound 1 prepared by the method described with suitable non-irritating excipients or carriers (such as cocoa butter, polyethylene glycol or suppository wax), which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[0378] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one pharmaceutically acceptable inert excipient or carrier (such as sodium citrate or dicalcium phosphate) and / or the following substances: a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; c) humectants such as glycerol; d) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) dissolution retardants such as paraffin; f) absorption promoters such as quaternary ammonium compounds; g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite; and / or i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also contain a buffer.

[0379] In soft and hard filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycol, similar types of solid compositions can also be used as fillers. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in the field of pharmaceutical formulation. They can optionally contain opacifiers and can also have a composition that optionally releases one or more active ingredients in a certain part of the intestinal tract only or preferentially in a delayed manner. Examples of usable embedded compositions include polymeric substances and waxes. In soft and hard filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycol, similar types of solid compositions can also be used as fillers.

[0380] The active compound may also be present in a microencapsulated form together with one or more excipients as indicated above. The solid dosage forms of tablets, dragees, capsules, pills and granules may be prepared with coatings and shells, such as enteric coatings, controlled release coatings and other coatings known in the field of pharmaceutical formulation. In such solid dosage forms, the active compound may be blended with at least one inert diluent (such as sucrose, lactose or starch). As generally practiced, such dosage forms may also include additional substances in addition to the inert diluent, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form may also include a buffer. They may optionally contain an emulsifier, and may also have a composition that optionally releases one or more active ingredients in a delayed manner only or preferentially in a certain part of the intestinal tract. Examples of usable embedded compositions include polymeric substances and waxes.

[0381] The dosage form for topical or transdermal administration of compound 1 prepared by the method includes ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant or patch. Active ingredient is mixed with a pharmaceutically acceptable carrier and any required preservative or buffer as may be needed under aseptic conditions. Ophthalmic preparations, ear drops and eye drops are also covered in the scope. In addition, the purposes of transdermal patches are covered, and the transdermal patches have the additional advantage of providing controlled delivery of compounds to the body. Such dosage forms can be prepared by dissolving or distributing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. Rate can be controlled by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or a gel.

[0382] According to one embodiment, a method of inhibiting protein kinase activity in a biological sample is described, the method comprising the step of contacting the biological sample with Compound 1 prepared by the method or a composition comprising the compound.

[0383] According to another embodiment, a method of inhibiting the activity of TYK2 or a mutant thereof in a biological sample is contemplated, the method comprising the step of contacting the biological sample with a compound or a composition comprising the compound. In certain embodiments, a method of irreversibly inhibiting the activity of TYK2 or a mutant thereof in a biological sample is described, the method comprising the step of contacting the biological sample with Compound 1 prepared by the method herein or a composition comprising the compound.

[0384] In another embodiment, a method of selectively inhibiting TYK2 relative to one or more of JAK1, JAK2, and JAK3 is described. In some embodiments, the selectivity of compound 1 produced by the methods herein is more than 2 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound is more than 5 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound is more than 10 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound is more than 50 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound is more than 100 times that of JAK1 / 2 / 3.

[0385] As used herein, the term "biological sample" includes, but is not limited to, cell cultures or extracts thereof; biopsy material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears or other body fluids or extracts thereof.

[0386] Inhibiting TYK2 (or its mutant) activity in a biological sample can be used for a variety of purposes known to those skilled in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological sample storage, and bioassays.

[0387] Another embodiment is directed to a method of inhibiting protein kinase activity in a patient, comprising the step of administering to the patient Compound 1 prepared by the methods herein, or a composition comprising the same.

[0388] Another embodiment relates to a method of inhibiting the activity of TYK2 or a mutant thereof in a patient, the method comprising administering to the patient a step of compound 1 prepared by the methods herein or a composition comprising the compound. According to certain embodiments, a method of reversibly or irreversibly inhibiting the activity of one or more TYK2 or mutants thereof in a patient, the method comprising administering to the patient a step of compound 1 prepared by the methods herein or a composition comprising the compound. In other embodiments, a method for treating a disorder mediated by TYK2 or a mutant thereof in a patient in need thereof is provided, the method comprising administering to the patient a step of compound 1 prepared by the methods herein or a pharmaceutically acceptable composition thereof. Such disorders are described in detail herein.

[0389] Depending on the particular disorder or disease to be treated, additional therapeutic agents that are normally administered to treat that disorder may also be present in the composition. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or disorder are referred to as "appropriate for the disease or disorder being treated."

[0390] Compound 1 prepared by the methods herein can also be advantageously used in combination with other therapeutic compounds. In some embodiments, the other therapeutic compounds are antiproliferative compounds. Such antiproliferative compounds include, but are not limited to, aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule-active compounds; alkylating compounds; histone deacetylase inhibitors; compounds that induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; anti-tumor antimetabolites; platinum compounds; compounds that target / reduce protein or lipid kinase activity and other anti-angiogenic compounds; compounds that target, reduce or inhibit the activity of protein or lipid phosphatases; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds for the treatment of hematological malignancies; compounds that target, reduce or inhibit Flt-3 activity; Hsp90 inhibitors, such as from Conforma Therapeutics' 17-AAG (allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010; temozolomide Kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine / chlorpromazine from CombinatoRx; MEK inhibitors, such as ARRY142886 from Array BioPharma, AZD6244 from AstraZeneca, PD181461 from Pfizer, and leucovorin. The term "aromatase inhibitor" as used herein relates to compounds that inhibit estrogen production (e.g., the conversion of the substrates androstenedione and testosterone into estrone and estradiol, respectively). The term includes, but is not limited to, steroids, particularly atamestane, exemestane and formestane, and specifically nonsteroids, particularly aminoglutethimide, rogletimide, pyridoglutethimide, trilostane, testolactone, ketoconazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name Aromasin TM Formestane is sold under the brand name Lentaron TM Fadroxil is sold under the brand name Afema TM Anastrozole is sold under the brand name Arimidex TM Letrozole is sold under the brand name Femara TM or Femar TM Aminoglutethimide is sold under the trade name Orimeten TM Combinations comprising a chemotherapeutic agent that is an aromatase inhibitor are particularly useful in the treatment of hormone receptor positive tumors, such as breast tumors.

[0391] As used herein, the term "anti-estrogen" refers to compounds that antagonize the effects of estrogen at the level of the estrogen receptor. The term includes, but is not limited to, tamoxifen, fulvestrant, raloxifene, and raloxifene hydrochloride. Tamoxifen is marketed under the trade name Nolvadex. TM Raloxifene hydrochloride is sold under the brand name Evista TM Fulvestrant is sold under the brand name Faslodex TMCombinations that may include a chemotherapeutic agent that is an antiestrogen are particularly useful in treating estrogen receptor positive tumors, such as breast tumors.

[0392] As used herein, the term "antiandrogen" refers to any substance that is capable of inhibiting the biological effects of androgens and includes, but is not limited to, bicalutamide (Casodex TM As used herein, the term "gonadorelin agonist" includes, but is not limited to, abarelix, goserelin, and goserelin acetate. Goserelin is available under the brand name Zoladex TM Application.

[0393] As used herein, the term "topoisomerase I inhibitors" include, but are not limited to, topotecan, gimatecan, irinotecan, camptothecian and its analogs, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be marketed, for example, in its commercial form (e.g., under the trademark Camptosar TM ) administration. Topotecan is sold under the brand name Hycamptin TM Sale.

[0394] As used herein, the term "topoisomerase II inhibitors" include, but are not limited to, anthracyclines such as doxorubicin (including liposomal formulations such as Caelyx TM ), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide is marketed under the trade name Etopophos TM Teniposide is sold under the trade name VM26-Bristol. Doxorubicin is sold under the trade name Acriblastin TM or Adriamycin TM Epirubicin is sold under the brand name Farmorubicin TM Idarubicin is marketed under the brand name Zavedos TM Mitoxantrone is sold under the trade name Novantron.

[0395] The term "microtubule active agent" refers to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors, including but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate and vinorelbine; discodermolide; cochicine and epothilone and its derivatives. Paclitaxel is sold under the trade name Taxol TM Docetaxel is sold under the brand name Taxotere TM Vinblastine sulfate is sold under the trade name Vinblastin RP TM Vincristine sulfate is sold under the trade name Farmistin TM Sale.

[0396] As used herein, the term "alkylating agent" includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan, or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name Cyclostin. TM Ifosfamide is sold under the brand name Holoxan TM Sale.

[0397] The term "histone deacetylase inhibitor" or "HDAC inhibitor" relates to compounds that inhibit histone deacetylase and have antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).

[0398] The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name Xeloda TM Gemcitabine is sold under the brand name Gemzar TM Sale.

[0399] As used herein, the term "platinum compound" includes, but is not limited to, carboplatin, cis-platin (cisplatinum) and oxaliplatin. Carboplatin can be obtained, for example, in its commercially available form (e.g., under the trademark Carboplat TM ) is administered. Oxaliplatin can be administered, for example, in the form as it is marketed (e.g. under the trademark Eloxatin TM ) application.

[0400] As used herein, the term "compounds that target / reduce the activity of a protein or lipid kinase or a protein or lipid phosphatase; or other anti-angiogenic compounds" includes, but is not limited to, protein tyrosine kinase and / or serine and / or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds that target, reduce or inhibit the activity of platelet-derived growth factor receptor (PDGFR), such as compounds that target, reduce or inhibit the activity of PDGFR, especially compounds that inhibit PDGF receptor, such as N-phenyl-2-pyrimidine-amine derivatives, such as imatinib, SU101, SU6668 and GFB-111; b) compounds that target, reduce or inhibit the activity of fibroblast growth factor receptor (FGFR); c) compounds that target, reduce or inhibit the activity of insulin-like growth factor receptor I (IGF-IR), such as compounds that target, reduce or inhibit the activity of IGF-IR, especially compounds that inhibit the kinase activity of IGF-I receptor or antibodies that target the extracellular domain of IGF-I receptor or its growth factor; d) compounds that target, reduce or inhibit Tr k receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds that target, reduce or inhibit the activity of the AxI receptor tyrosine kinase family; f) compounds that target, reduce or inhibit the activity of the Ret receptor tyrosine kinase; g) compounds that target, reduce or inhibit the activity of the Kit / SCFR receptor tyrosine kinase, such as imatinib; h) compounds that target, reduce or inhibit the activity of the c-kit receptor tyrosine kinase, which is part of the PDGFR family, such as compounds that target, reduce or inhibit the activity of the c-Kit receptor tyrosine kinase. i) compounds that target, reduce or inhibit the activity of members of the c-Abl family, their gene fusion products (e.g., BCR-Abl kinase) and mutants, such as compounds that target, reduce or inhibit the activity of c-Abl family members and their gene fusion products, such as N-phenyl-2-pyrimidine-amine derivatives, such as imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825); j) compounds that target, decrease or inhibit the activity of members of the Raf family of protein kinase C (PKC) and serine / threonine kinases, MEK, SRC, JAK / pan-JAK, FAK, PDK1, PKB / Akt, Ras / MAPK, PI3K, SYK, BTK and TEC families and / or members of the cyclin-dependent kinase family (CDK), including staurosporine derivatives such as midostaurin;Examples of other compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; Ilmofosine; RO 318220 and RO320432; GO 6976; Isis 3521; LY333531 / LY379196; Isoquinoline compounds; FTIs; PD184352 or QAN697 (P13K inhibitors) or AT7519 (CDK inhibitors); k) compounds that target, decrease or inhibit the activity of protein tyrosine kinases, such as compounds that target, decrease or inhibit the activity of protein tyrosine kinases, including imatinib mesylate (Gleevec; TM ) or tyrosine phosphorylation inhibitors, such as tyrosine phosphorylation inhibitor A23 / RG-50810; AG 99; tyrosine phosphorylation inhibitor AG 213; tyrosine phosphorylation inhibitor AG 1748; tyrosine phosphorylation inhibitor AG 490; tyrosine phosphorylation inhibitor B44; tyrosine phosphorylation inhibitor B44(+) spiegelmer; tyrosine phosphorylation inhibitor AG555; AG 494; tyrosine phosphorylation inhibitor AG 556, AG957 and adaphostin (4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); 1) targeting, decreasing or inhibiting the epidermal growth factor family of receptor tyrosine kinases (EGFR1 in the form of homodimers or heterodimers) Compounds that inhibit the activity of ErbB2, ErbB3, ErbB4) and their mutants, such as compounds that target, reduce or inhibit the activity of the epidermal growth factor receptor family, especially compounds, proteins or antibodies that inhibit members of the EGF receptor tyrosine kinase family (such as EGF receptor, ErbB2, ErbB3 and ErbB4) or bind to EGF or EGF-related ligands, CP 358774, ZD 1839, ZM105180; trastuzumab (Herceptin TM ), cetuximab (Erbitux TM), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569, GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives; m) compounds that target, decrease or inhibit the activity of c-Met receptors, such as compounds that target, decrease or inhibit the activity of c-Met, especially compounds that inhibit c-Met receptors or target c- Compounds that target, decrease or inhibit the kinase activity of one or more JAK family members (JAK1 / JAK2 / JAK3 / TYK2 and / or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-1 o) compounds that target, decrease or inhibit the kinase activity of PI3 kinase (PI3K), including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, sib), XL-147, XL-765 and idelalisib; and q) compounds that target, reduce or inhibit the signaling effects of the hedgehog protein (Hh) or smoothened receptor (SMO) pathway, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib and IPI-926 (saridegib).

[0401] The term "PI3K inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3-kinase family, including but not limited to PI3Kα, PI3Kγ, PI3Kδ, PI3Kβ, PI3K-C2α, PI3K-C2β, PI3K-C2γ, Vps34, p110-α, p110-β, p110-γ, p110-δ, p85-α, p85-β, p55-γ, p150, p101 and p87. Examples of PI3K inhibitors include, but are not limited to, ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparix, pitrilis, PF-4691502, BYL-719, datelix, XL-147, XL-765, and idelalisib.

[0402] As used herein, the term "BTK inhibitor" includes, but is not limited to, compounds having inhibitory activity against Bruton's Tyrosine Kinase (BTK), including, but not limited to, AVL-292 and ibrutinib.

[0403] The term "SYK inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against spleen tyrosine kinase (SYK), including, but not limited to, PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.

[0404] The term "Bcl-2 inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including, but not limited to, ABT-199, ABT-731, ABT-737, apogossypol, Ascenta's pan-Bcl-2 inhibitor, curcumin (and its analogs), dual Bcl-2 / Bcl-xL inhibitors (Infinity Pharmaceuticals / Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and its analogs; see WO2008118802), navitoclax (and its analogs, see US7390799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and its analogs, see WO2004106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ. of Michigan) and venetoclax. In some embodiments, the Bcl-2 inhibitor is a small molecule therapeutic. In some embodiments, the Bcl-2 inhibitor is a peptidomimetic.

[0405] Other examples of BTK inhibitory compounds and conditions that can be treated by such compounds in combination with the compounds herein can be found in WO2008039218 and WO2011090760, the entire contents of which are incorporated herein by reference.

[0406] Other examples of SYK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds herein can be found in WO2003063794, WO2005007623 and WO2006078846, the entire contents of which are incorporated herein by reference.

[0407] Other examples of PI3K inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds herein can be found in WO2004019973, WO2004089925, WO2007016176, US8138347, WO2002088112, WO2007084786, WO2007129161, WO2006122806, WO2005113554 and WO2007044729, the entire contents of which are incorporated herein by reference.

[0408] Other examples of JAK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds herein can be found in WO2009114512, WO2008109943, WO2007053452, WO2000142246 and WO2007070514, the entire contents of which are incorporated herein by reference.

[0409] Other antiangiogenic compounds include compounds that have another mechanism for their activity (e.g., not related to protein or lipid kinase inhibition), such as thalidomide. TM ) and TNP-470.

[0410] Examples of proteasome inhibitors that can be used in combination with Compound 1 prepared by the methods herein include, but are not limited to, bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.

[0411] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, for example, inhibitors of phosphatase 1, phosphatase 2A or CDC25, such as okadaic acid or a derivative thereof.

[0412] Compounds that induce cell differentiation processes include, but are not limited to, retinoic acid, α-, γ- or δ-tocopherol or α-, γ- or δ-tocotrienol.

[0413] The term cyclooxygenase inhibitors as used herein include, but are not limited to, Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acids and derivatives such as celecoxib (Celebrex TM ), etoricoxib, valdecoxib or 5-alkyl-2-arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, lumiracoxib.

[0414] As used herein, the term "bisphosphonates" includes, but is not limited to, etridonic acid, clodronic acid, tiludronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, and zoledronic acid. TM Clodronic acid is sold under the trade name Bonefos TM Tiludronic acid is sold under the brand name Skelid TM Pamidronate is sold under the brand name Aredia TM Alendronate is sold under the brand name Fosamax TM Ibandronic acid is sold under the brand name Bondranat TM Risedronate is sold under the brand name Actonel TM Zoledronic acid is sold under the brand name Zometa TM The term "mTOR inhibitor" refers to compounds that inhibit the mammalian target of rapamycin (mTOR) and have antiproliferative activity, such as sirolimus. Everolimus (Certican TM ), CCI-779 and ABT578.

[0415] As used herein, the term "heparanase inhibitor" refers to a compound that targets, reduces or inhibits the degradation of heparan sulfate. The term includes, but is not limited to, PI-88. As used herein, the term "biological response modifier" refers to a lymphokine or interferon.

[0416] As used herein, the term "inhibitor of an oncogenic isoform of Ras (such as H-Ras, K-Ras or N-Ras)" refers to a compound that targets, decreases or inhibits the oncogenic activity of Ras; for example, a "farnesyl transferase inhibitor" such as L-744832, DK8G557 or R115777 (Zarnestra TM ). As used herein, the term "telomerase inhibitor" refers to a compound that targets, reduces or inhibits telomerase activity. Compounds that target, reduce or inhibit telomerase activity are particularly compounds that inhibit telomerase receptors, such as telomestatin.

[0417] The term "methionine aminopeptidase inhibitor" as used herein refers to a compound that targets, reduces or inhibits the activity of methionine aminopeptidase. Compounds that target, reduce or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or its derivatives.

[0418] As used herein, the term "proteasome inhibitor" refers to a compound that targets, decreases or inhibits the activity of the proteasome. Compounds that target, decrease or inhibit the activity of the proteasome include, but are not limited to, bortezomib (Velcade TM ) and MLN341.

[0419] As used herein, the term "matrix metalloproteinase inhibitors" or ("MMP" inhibitors) includes, but is not limited to, collagen peptide mimetics and non-peptide mimetic inhibitors, tetracycline derivatives, such as the hydroxamate peptide mimetic inhibitor batimastat and its orally bioavailable analogs marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211, MMI270B or AAJ996.

[0420] As used herein, the term "compounds for treating hematological malignancies" includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds that target, decrease or inhibit the activity of the FMS-like tyrosine kinase receptor (Flt-3R); interferons, 1-β-D-arabinofuranosylcytosine (ara-c) and bisulfan; ALK inhibitors, which are compounds that target, decrease or inhibit anaplastic lymphoma kinase; and Bcl-2 inhibitors.

[0421] Compounds that target, decrease or inhibit the activity of the FMS-like tyrosine kinase receptor (Flt-3R) are in particular compounds, proteins or antibodies that inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, staurosporine derivatives, SU11248 and MLN518.

[0422] As used herein, the term "HSP90 inhibitor" includes, but is not limited to, compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90; compounds that degrade, target, reduce or inhibit HSP90 client proteins via the ubiquitin proteasome pathway. Compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies that inhibit the ATPase activity of HSP90, such as 17-allylamino, 17-demethoxygeldanamycin (17AAG, a geldanamycin derivative); other geldanamycin-related compounds; radicicol and HDAC inhibitors.

[0423] As used herein, the term "anti-proliferative antibodies" includes, but is not limited to, trastuzumab (Herceptin TM ), trastuzumab-DM1, erbitux, bevacizumab (Avastin TM ), rituximab PRO64553 (anti-CD40) and 2C4 antibodies. Antibodies refer to intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibody fragments, so long as the fragments exhibit the desired biological activity.

[0424] For the treatment of acute myeloid leukemia (AML), the compounds herein can be used in combination with standard leukemia therapies, particularly in combination with therapies for the treatment of AML. Specifically, compound 1 prepared by the methods herein can be administered in combination with, for example, farnesyl transferase inhibitors and / or other drugs that can be used to treat AML, such as daunomycin, adriamycin, Ara-C, VP-16, teniposide, mitoxantrone, idarubicin, carboplatin, and PKC412. In some embodiments, the method is a method for treating AML associated with ITD and / or D835Y mutations, comprising administering compound 1 prepared by the methods herein together with one or more FLT3 inhibitors. In some embodiments, the FLT3 inhibitor is selected from quizartinib (AC220), a staurosporine derivative (e.g., midostaurin or lestaurtinib), sorafenib, tandutinib, LY-2401401, LS-104, EB-10, famitinib, NOV-110302, NMS-P948, AST-487, G-749, SB-1317, S-209, SC-110219, AKN-028, fedratinib, tozasertib, and sunitinib. In some embodiments, the FLT3 inhibitor is selected from quizartinib, midostaurin, lestaurtinib, sorafenib, and sunitinib.

[0425] Other anti-leukemic compounds include, for example, Ara-C (a pyrimidine analog), which is a 2'-α-hydroxyribose (arabinoside) derivative of deoxycytidine. Also included are purine analogs of hypoxanthine, 6-mercaptopurine (6-MP), and fludarabine phosphate. Compounds that target, reduce, or inhibit the activity of histone deacetylase (HDAC) inhibitors, such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA), inhibit the activity of an enzyme called histone deacetylase. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly known as FR901228), Trichostatin A and compounds disclosed in US 6,552,065, including but not limited to N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-acrylamide or a pharmaceutically acceptable salt thereof and N-hydroxy-3-[4-[(2-hydroxyethyl){2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-acrylamide or a pharmaceutically acceptable salt thereof, especially lactate. As used herein, a somatostatin receptor antagonist refers to a compound that targets, treats or inhibits a somatostatin receptor, such as octreotide and SOM230. Tumor cell destruction methods refer to methods such as ionizing radiation. The term "ionizing radiation" referred to above and below means ionizing radiation that occurs in the form of electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in (but not limited to) radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, Principles and Practice of Oncology, Devita et al., eds., 4th edition, volume 1, pages 248-275 (1993).

[0426] Also included are EDG binders and ribonucleotide reductase inhibitors. As used herein, the term "EDG binder" refers to a class of immunosuppressants that regulate lymphocyte recirculation, such as FTY720. The term "ribonucleotide reductase inhibitor" refers to pyrimidine or purine nucleoside analogs, including but not limited to fludarabine and / or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C to resist ALL) and / or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1H-isoindole-1,3-dione derivatives.

[0427] Specifically, compounds, proteins or monoclonal antibodies of VEGF, such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; Angiostatin TM ;Endostatin TM ; anthranilamide; ZD4190; ZD6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamers, such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibodies, Angiozyme (RPI 4610) and bevacizumab (Avastin TM ).

[0428] As used herein, photodynamic therapy refers to therapy that uses certain chemicals known as photosensitive compounds to treat or prevent cancer. Examples of photodynamic therapy include the use of photosensitive agents such as Visudyne TM and porfimersodium compounds.

[0429] As used herein, angiostatic steroids refer to compounds that block or inhibit angiogenesis, such as anecortave, triamcinolone, hydrocortisone, 11-alpha-epihydrocortisol, cortexolone, 17alpha-hydroxyprogesterone, corticosterone, deoxycorticosterone, testosterone, estrone, and dexamethasone.

[0430] Implants containing corticosteroids refer to compounds such as fluocinolone and dexamethasone.

[0431] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormone compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or various compounds or compounds with other or unknown mechanisms of action.

[0432] Compound 1 prepared by the methods herein can also be used as a co-therapeutic compound for use in combination with other bulk drugs (such as anti-inflammatory, bronchodilatory or antihistamine bulk drugs), especially for the treatment of obstructive or inflammatory airway diseases (such as those mentioned above), for example, as a synergist of the therapeutic activity of such drugs or as a means of reducing the required dose or potential side effects of such drugs. Compound 1 prepared by the methods herein can be mixed with other bulk drugs in a fixed pharmaceutical composition, or it can be administered separately before, at the same time or after other bulk drugs. Therefore, a combination of Compound 1 prepared by the methods described above and an anti-inflammatory, bronchodilatory, antihistamine or antitussive bulk drug is provided, wherein the compound and the bulk drug are in the same or different pharmaceutical compositions.

[0433] Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids, such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate; nonsteroidal glucocorticoid receptor agonists; LTB4 antagonists, such as LY293111, CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247; LTD4 antagonists, such as montelukast and zafirlukast; PDE4 inhibitors, such as cilomilast Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SeICID(TM) CC-10004 (Celgene), VM554 / UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo); A2a agonists; A2b antagonists; and beta-2 adrenergic receptor agonists, such as albuterol, salbutamol, iproterol, terbutaline, salmeterol, fenoterol, procaterol and especially formoterol and pharmaceutically acceptable salts thereof. Suitable bronchodilators include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium bromide salts and CHF 4226 (Chiesi) and glycopyrrolate.

[0434] Suitable antihistamine APIs include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine.

[0435] Other useful combinations of compounds with anti-inflammatory drugs are those with chemokine receptor (e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5) antagonists, particularly CCR-5 antagonists such as the Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D, and Takeda antagonists such as N-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-ammonium chloride (TAK-770).

[0436] The structures of the active compounds identified by code names, generic names or trade names can be taken from the current edition of the standard compendium "The Merck Index" or from databases of, for example, international patents (eg IMS World Publications).

[0437] Compound 1 prepared by the methods herein can also be used in combination with known treatment procedures, such as administration of hormones or radiation. In certain embodiments, provided compounds are used as radiosensitizers, particularly for treating tumors that exhibit poor sensitivity to radiation therapy.

[0438] Compound 1 prepared by the methods herein can be administered alone or in combination with one or more other therapeutic compounds, and possible combination therapies take the form of fixed combinations, or compound 1 prepared by the methods herein and one or more other therapeutic compounds are staggered or administered independently of each other, or a fixed combination is administered in combination with one or more other therapeutic compounds. In addition or in addition, compound 1 prepared by the methods herein can be administered in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these therapies for tumor therapy. As described above, long-term therapy is also possible, as is adjuvant therapy in the context of other treatment strategies. Other possible treatments are therapies used to maintain the patient's status after tumor regression, or even (for example) chemopreventive therapy in patients at risk.

[0439] Those other agents may be administered separately from the compositions containing the compounds as described herein as part of a multiple dose regimen. Alternatively, those agents may be part of a single dosage form that is mixed together with Compound 1 prepared by the methods herein in a single composition. If administered as part of a multiple dose regimen, the two active agents may be presented simultaneously, sequentially, or within a certain time period of each other, typically within five hours of each other.

[0440] As used herein, the terms "combination", "combined" and related terms refer to the simultaneous or sequential administration of therapeutic agents. For example, Compound 1 prepared by the methods herein can be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Therefore, a single unit dosage form comprises Compound 1 prepared by the methods herein, other therapeutic agents and a pharmaceutically acceptable carrier, adjuvant or vehicle.

[0441] The amount of both the compound of the invention and other therapeutic agent (in those compositions comprising other therapeutic agents as described above) that can be combined with the carrier material to produce a single dosage form will vary depending on the host being treated and the particular mode of administration. Preferably, the composition should be formulated so that a dose of 0.01-100 mg / kg body weight / day of the compound of the invention can be administered.

[0442] In those compositions comprising an additional therapeutic agent, the additional therapeutic agent and compound 1 prepared by the methods herein may act synergistically. Thus, the amount of the additional therapeutic agent in such compositions will be less than the amount required in a monotherapy utilizing only the therapeutic agent. In such compositions, a dose of 0.01-1,000 μg / kg body weight / day of the additional therapeutic agent may be administered.

[0443] The amount of the other therapeutic agent present in the composition comprising Compound 1 prepared by the methods herein will not exceed the amount normally administered in a composition comprising the therapeutic agent as the only active agent. Preferably, the amount of the other therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount normally present in a composition comprising the agent as the only therapeutically active agent. Preferably, the amount of the other therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount normally present in a composition comprising the agent as the only therapeutically active agent.

[0444] Compound 1 or its pharmaceutical composition prepared by the methods herein can also be incorporated into compositions for coating implantable medical devices such as prostheses, artificial valves, vascular grafts, stents and catheters. For example, vascular stents have been used to overcome restenosis (restenosis of the blood vessel wall after injury). However, patients using stents or other implantable devices are at risk of blood clot formation or platelet activation. These unwanted effects can be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with Compound 1 are another embodiment.

[0445] In some embodiments, a medicament is provided, which comprises at least Compound 1 prepared by the method described herein or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

[0446] All features of each aspect of the invention apply mutatis mutandis to all other aspects.

[0447] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and should not be construed as limiting the present invention in any manner.

[0448] Example

[0449] Example 1: Synthesis of Compound 1

[0450] Scheme 2 shown below illustrates the detailed synthetic procedure used to produce compounds 6, 2, and 1.

[0451] Scheme 2: Detailed synthetic procedure for the synthesis of compound 1

[0452]

[0453] Step 1: Synthesis of compound 6

[0454] Step 1

[0455]

[0456] Compound 7 can be prepared as shown in the scheme below.

[0457]

[0458] Total yield: 29.2%. This method was used to prepare compound 7 on a 60.0 kg scale starting from 140.0 kg of ethyl 3-amino-1H-pyrazole-4-carboxylate. This stage produced 29.31 kg of 7 with a chemical purity of 99.0% and 41.16 kg of 7 with a chemical purity of 98.8%.

[0459] Compound 7 (1.9 Kg, 5.82 mol, 1.00 equiv), the hydrochloride salt of compound 5 (800.9 g, 5.82 mol, 1.00 equiv), DIPEA (4.5 Kg, 34.92 mol, 6.00 equiv), T3P (50% in EtOAc) (7.4 Kg, 11.64 mol, 2.00 equiv) were dissolved in DCM (50.3 Kg, 48.0 L, 20 volumes) at 0°C ± 5°C.

[0460] After stirring at 0°C ± 5°C for 1 hour, HPLC (30 min method, UV 242 nm) of the reaction sample showed 81% of the desired product, Compound 6.

[0461] After stirring the reaction for another hour at 0°C ± 5°C, HPLC of the second reaction sample showed 82% of the desired product compound 6. The sum of the starting material compound 7 and the two activated ester intermediates was 18%. At this stage, applicants performed a water quench.

[0462] Reaction quenching and workup

[0463] The reaction mixture was quenched with water (3.8 Kg, 3.8 L, 2 volumes). DCM was distilled and the residue was dissolved in EtOAc (68.6 Kg, 76.1 L, 40 volumes). 2 CO 3 Aqueous solution (33.4 Kg, 15 volumes), 10% K 2 CO 3 (2 x 19.0 Kg, 2 x 10 vol) and washed the organic layer.

[0464] HPLC analysis of the organic layer showed 99.05% of the desired product, Compound 6. The sum of the starting material, Compound 7, and two by-product activated ester intermediates was 1%.

[0465] After passing the purity test, the organic layer was washed sequentially with water (9.5 Kg, 5 volumes) and brine (2 x 9.5 Kg, 2 x 5 volumes). The resulting organic layer was filtered over a silica plug (5.7 Kg, 2% w / w) with 5.0 Kg of sand on top. The silica plug was washed with EtOAc (34.4 Kg, 38.0 L, 20 volumes).

[0466] Trituration in n-heptane

[0467] The combined filtrate was concentrated to about 6 L (3.2 volumes). n-Heptane (7.8 Kg, 11.4 L, 6 volumes) was slowly added over a 30 minute period. The mixture was stirred at 20°C ± 5°C for at least 2 hours (actual stirring time: overnight, 15.4 hours). The solid was collected by filtration and washed with n-heptane [2×5.2 Kg (2×7.6 L, 2×4 volumes)].

[0468] Drying and packaging

[0469] After drying in a vacuum tray dryer at 43°C for 23 hours, a sample was taken out for LOD (limit of detection) test which showed a 0.35% LOD result. The material was packaged to obtain 1.73 Kg of product compound 6 as a white solid in 72.4% yield. 1 H NMR (DMSO-d 6)ppm:1.29(s,9H),1.51(m,2H),2.04(m,2H),3.22(s,3H),3.32(s,3H),3.84(m,1H),4.28(m,1H),7.53(s,1H),8.03(d,1H),8.63(s,1H).

[0470] Step 2: Synthesis of compound 2

[0471]

[0472] Compound 4 can be prepared as shown in the scheme below.

[0473]

[0474] Total yield: 74.5%. The above route was used to deliver 3x20 kg of 4. The production batch initially used about 18.0 kg (corrected by assay) of 3-aminopyridin-2-ol and about 22.2 kg of 2-fluoropyridine. This phase produced 23.91 kg of 4 with a chromatographic purity of 99.8%, 22.84 kg of 4 with a chromatographic purity of 99.8%, and 22.90 kg of 4 with a chromatographic purity of 99.8%, respectively.

[0475] Compound 6 (1.7 Kg, 4.15 mol, 1.00 equiv), compound 4 (799.3 g, 4.27 mol, 1.03 equiv), Pd(OAc) in DME (26.5 Kg, 30.6 L, 18 vol) were added at 80°C ± 5°C. 2 (18.0 g, 0.08 mol, 0.020 equiv), Xantphos (46.3 g, 0.08 mol, 0.020 equiv), K 2 CO 3 (1.26 Kg, 9.13 mol, 2.20 equiv) were combined in a 50 gallon tank. The reaction was complete after 4 hours at 80°C. HPLC (UV 266 nm) analysis of the reaction mixture showed 0.06% of compound 6 remaining.

[0476] Two batches of crude solid

[0477] After confirming that the reaction is complete, the reaction mixture is cooled to 20°C ± 5°C and stirred at 20°C ± 5°C for at least 30 minutes. The solid is filtered and washed twice with MTBE (4.2Kg and 3.6Kg) to obtain the "first batch of crude solids". The filtrate is transferred back to the 50-gallon reactor. The mixture is concentrated until no distillate is observed. DME (3.3Kg) and MTBE (5.6Kg) are added. The mixture is stirred at 20°C ± 5°C for at least 30 minutes. The solid is collected by filtration and washed with MTBE (6.1Kg) to obtain the "second batch of crude solids".

[0478] Extraction with DCM

[0479] The two batches of crude solids obtained were combined and transferred to a 50-gallon reactor. DCM (37.9 Kg) and water (28.5 Kg) were added. The mixture was stirred at 20°C ± 5°C for at least 15 minutes and then allowed to settle for phase separation. The mixture was left to settle overnight (17.5 hours) to eliminate emulsions.

[0480] After the DCM layer was transferred, the aqueous layer was back extracted twice with DCM (12.6 Kg each time). The first back extraction was allowed to settle for 6 hours, and the second back extraction was allowed to settle overnight (15 hours).

[0481] Optionally, the DCM / water mixture can be filtered through diatomaceous earth to remove insoluble solids before phase separation. Laboratory runs have shown that phase separation becomes very fast after filtering and removing insoluble solids. In addition, product losses due to unclear phase separation can be avoided.

[0482] Wash with aqueous N-Ac-L-Cys, water and brine

[0483] The combined product in DCM solution was washed three times with 10% aqueous N-Ac-L-cysteine ​​(NAC) (38.0 Kg each time). After settling for 30 minutes, a clear phase separation was obtained. The DCM layer was then washed with water (19.0 Kg) and saturated aqueous NaCl solution (19.0 Kg) in sequence.

[0484] Activated carbon treatment

[0485] After NAC treatment, water and brine washing, the product solution in DCM was distilled and the solvent was exchanged to THF (twice, using 5.1Kg THF). Activated carbon (340.0g, 20wt% relative to 1.7Kg of compound 6 as starting material) and THF (30.4Kg, 34.2L, 20 volumes relative to 1.7Kg of compound 6 as starting material) were added. The mixture was heated to 60°C ± 5°C and stirred at 60°C ± 5°C for at least 6 hours (stirred overnight, about 18 hours). Then, the mixture was cooled to 20°C ± 5°C and the charcoal was filtered out through diatomaceous earth (3.2Kg). The diatomaceous earth pad was washed with THF (5.0Kg). A sample of the THF solution was taken. The sample solution was concentrated and tested for palladium (Pd) content analysis. It was found that the Pd content was <7.88ppm.

[0486] SPM32 Processing

[0487] Three SPM32 treatments (570 g SPM32 per treatment) were carried out in THF at 60°C ± 5°C for at least 6 hours. After cooling to 20°C ± 5°C, the scavenger SPM32 was filtered off through diatomaceous earth and the diatomaceous earth was washed with THF. The three treatments were as follows:

[0488] The first SPM32 treatment (570g SPM32): 60°C ± 5°C for 18 hours, diatomaceous earth: 2.4 Kg, THF for diatomaceous earth washing: 7.3 Kg.

[0489] Second SPM32 treatment (570g SPM32): 60°C ± 5°C for 20.4 hours, diatomaceous earth: 1.5 Kg, THF for diatomaceous earth washing: 7.2 Kg.

[0490] The third SPM32 treatment (570g SPM32): 60°C ± 5°C for 21 hours, diatomaceous earth: 1.5 Kg, THF for diatomaceous earth washing: 8.1 Kg.

[0491] A sample of the THF solution was taken. The sample solution was concentrated and tested for Pd content analysis. The Pd content was found to be <7.94 ppm.

[0492] Distillation

[0493] After SPM32 treatment, the THF solution was concentrated to approximately 20 L in a 50-gallon tank. The THF solution was transferred to a clean drum. The tank was rinsed with THF (10.4 Kg) and the rinse was transferred to the drum. Product separation was performed in a 100 L reactor as follows

[0494] Distillation in a 100 L reactor : The THF solution in the drum was transferred to a 100 L reactor and concentrated under vacuum to about 10 L. MTBE (14.8 Kg, 20.0 L) was added and the mixture was concentrated to about 10 L. The MTBE exchange distillation was repeated twice more (14.8 Kg MTBE each time and concentrated to about 10 L).

[0495] Grinding in MTBE

[0496] After the solvent was distilled (about 10 L remaining), MTBE (11.1 Kg, 15 L) was added. The mixture was heated to 50°C ± 5°C and stirred at 50°C ± 5°C for 1 hour. After cooling to 20°C ± 5°C, the mixture was stirred at 20°C ± 5°C overnight (19.5 hours). The batch was filtered and the wet cake was washed twice with MTBE (2.8 Kg and 4.8 Kg respectively). A sample of the wet cake was taken out and analyzed by HPLC, which showed a purity of 99.29%.

[0497] Drying and packaging

[0498] The material was dried in a vacuum tray dryer at ≤45°C for at least 16 hours. After drying at 43°C for 21.7 hours, a sample was taken out for LOD testing, which showed an LOD of 0.88%. The material was packaged. 1.5 Kg of compound 2 was obtained as a white solid with a yield of 65.2%. 1 H NMR (DMSO-d 6 )ppm:1.33(s,9H),1.50(m,2H),2.10(m,2H),3.21(s,3H),3.25(s,3H),3.77(m,1H),4.34(m,1H),6.49(m,1H),7.18(s,1H) ,7.55(dd,1H),7.71(dd,1H),7.88(d,1H),8.0(d,1H),8.05(dd,1H),8.29(s,1H),8.5(dd,1H),8.65(dd,1H),9.75(s,1H).

[0499] Synthesis of reagent compound 5

[0500] Compound 5 used in the above scheme can be prepared from cyclobutanone according to the scheme and sequence shown below.

[0501]

[0502] Cyclobutanone was converted to 2-bromocyclobutane-1-one by the following steps. 2Under protection, DCM (1330kg, 10 volumes) was added to a 2000L stainless steel reactor, followed by the addition of cyclobutanone (100Kg, 1.0 equivalents) and TEA (216.6kg, 1.5 equivalents). Cooled to -15°C to -25°C. TMSOTf (381.1kg, 1.2 equivalents) was added dropwise to the reactor at -15°C to -25°C for about 7 hours. Stirred for 2 hours at -15°C to -25°C. N-bromosuccinimide (NBS) (253.3kg, 1.0 equivalents) was added in batches at -15°C to -25°C for about 16 hours. Stirred for 2 hours at -15°C to -25°C. Warmed to 0°C-10°C, soft water (200kg, 2 volumes) was then added and stirred for 20 minutes at 10°C-20°C. The mixture was transferred to a 3000L glass-lined reactor, water (300kg, 3.0 volumes) was added, and stirred at 20°C-30°C for 20 minutes. The lower organic layer was separated and collected. The organic layer was washed with soft water (500kg, 5 volumes). 0.5N HCl (533kg, 5 volumes) was added to the organic layer, and then stirred at 10°C-20°C for 1 hour. The lower organic layer was separated and collected. The organic layer was washed with soft water (500kg, 5 volumes). The organic layer was washed with 10% brine (535kg, 5 volumes). The organic layer was concentrated to 2-3 volumes under a vacuum of no more than 35°C. DCM (665kg, 5 volumes) was added, and then concentrated to 1-2 volumes under a vacuum of no more than 35°C. This operation was repeated 2 times to remove water. Samples were taken for KF (standard: KF≤0.5%; result <0.01%). The residue was collected to give 2-bromocyclobutane-1-one as a light brown oil (331.8 kg in DCM, assay: 32%, 106.3 kg, KF: <0.01%, assay yield: 50%).

[0503] 2-Bromocyclobutane-1-one was converted to 2-(dibenzylamino)cyclobutane-1-one according to the following steps: 2 Under protection, DCM (707 kg, 5 volumes) was added to a 3000 L glass-lined reactor, followed by Bn 2NH (140 kg, 1.0 equiv) and DIPEA (115 kg, 1.25 equiv). 2-Bromocyclobutane-1-one (106 kg, 1.0 equiv) was added to the reactor at 15°C-25°C. Stirred for 16 hours at 15°C-25°C. Concentrated to 4-5 volumes under vacuum at no more than 40°C. EtOAc (572 kg, 6 volumes) was added, and then concentrated to 4-5 volumes under vacuum at no more than 40°C. EtOAc (572 kg, 6 volumes) was added. Washed once with water (636 kg, 6 volumes) (emulsion layer separated into aqueous layer). Washed once with 2% brine (649 kg, 6 volumes). EtOAc was extracted with 1N HCl (2×636 L, 1×318 L; 2×6 volumes, 1×3 volumes), and the aqueous layers were combined. The pH of the aqueous phase was adjusted to 9-10 with 20% NaOH. NaCl (212 kg, 2 w / w) was added and stirred until the solids dissolved. The aqueous layer was extracted once with THF (755 kg, 8 volumes). The aqueous layer was extracted once again with THF (472 kg, 5 volumes). The organic layers were combined and washed once with 10% brine (340 kg, 3 volumes). The organic layers were collected to give a light yellow solution of 2-(dibenzylamino)cyclobutane-1-one (1155 kg THF solution, assay: 14.98%, 173 kg of 5028-2 (corrected assay), purity: 93.0% (Bn 2 NH: 3.0%), KF: 7.9%, assay yield: 92%), which was used in the next reaction sequence.

[0504] 2-(Dibenzylamino)cyclobutan-1-one was converted to racemic trans-2-(dibenzylamino)cyclobutan-1-ol according to the following sequence: 2 Under protection, the 2-(dibenzylamino)cyclobutane-1-one solution (775 kg, containing 116 kg of 2-(dibenzylamino)cyclobutane-1-one) from the previous sequence was added to a 2000 L stainless steel reactor. Soft water (47 kg, 0.41 volume, because the THF solution contains 0.59 volume of water) and THF (266 kg, 2.68 volume) were added to the reactor. Cool to -50°C to -60°C. NaBH 4(16.5kg, 1.0 equivalent) was added to the reactor in several batches. Stirred for 1 hour at -50°C to -60°C. Warmed to -10°C, and acetone (90.5kg, 1 volume) was added dropwise to quench the reaction. Soft water (406kg, 3.5 volumes) was added to the reaction at ≤30°C. MTBE (429kg, 5 volumes) was added to dilute the reaction mixture. The mixture was separated and the aqueous layer was extracted with MTBE (172kg, 2 volumes), and the organic layers were combined. The organic layer was washed with 5% brine (300kg, 2.5 volumes). The organic phase was washed with 20% brine (348kg, 2.5 volumes). The organic layer was concentrated to 220L (1.9 volumes, target: 1-2 volumes) under a vacuum of no more than 45°C. n-heptane (6.0 volumes) was added. n-heptane (3.0 volumes) was added. Concentrated to 4-5 volumes under a vacuum of no more than 45°C. n-heptane (3.0 volumes) was added. Stir at 15°C-25°C until a large amount of solid precipitates (not less than 3 hours). Heat to 40°C-45°C, stir until material (adhering to the reactor wall) enters the system, then add n-heptane (2.0 volumes). Cool to 10°C-20°C and stir for not less than 3 hours. Filter and wash the filter cake with n-heptane (2.0 volumes). Dry under vacuum below 35°C until KF ≤ 0.5%, then sample for LOD and report the results. Collect the product to obtain off-white solid racemic trans-2-(dibenzylamino)cyclobutan-1-ol (66.0 kg, P: 98.7% (Bn 2 NH: 0.51%, cis: 0.56%), isolated yield: 56.4%).

[0505] Racemic trans-2-(dibenzylamino)cyclobutan-1-ol was enzymatically resolved according to the following sequence: 2 Acetone (1422 kg, 20 volumes) was added to the 3000 L reactor under protection. Stirring was carried out for 20 minutes, and a sample was taken for KF (standard: KF≤0.5%, result: KF=0.30%). 2 Racemic trans-2-(dibenzylamino)cyclobutan-1-ol (95.8 kg, 1.0 equivalent) was added to the reactor under N 2 Novozymes 435 lipase (18.84 kg, 0.2 w / w) was added to the reactor under protection. The mixture was stirred at 20°C-25°C for 0.5 h. 2Succinic anhydride (23.3 kg, 0.65 eq) was added to the reactor at 20°C-25°C under protection. Stir at 20°C-25°C for 26 hours. Filter and wash the filter cake 3 times with MTBE (1 volume). Water (1.0 eq) was added to the filtrate. All the filtrate was collected and concentrated to 1-3 volumes under vacuum below 40°C. MTBE (5.0 volumes) was added to the residue and concentrated to 1-3 volumes under vacuum below 40°C. This procedure was repeated twice. The residue was treated with MTBE (10 volumes) and 2.5% K 2 CO 3 The mixture was diluted with aqueous solution (6 volumes) and then stirred at 10°C-15°C for 0.5 hours. The mixture was separated and heated at 10°C-15°C with 2.5% K 2 CO 3 The MTBE phase was extracted with aqueous solution (2*6 volumes) to ensure that no esters were introduced into the MTBE. All aqueous phases were combined and washed with MTBE (2*2 volumes) (note: the solids at the interface were separated into the aqueous phase). Solid NaOH (4.0 equiv.) was added to the aqueous phase in portions below 10°C. Stirred for more than 4 hours at 15°C-20°C. The reaction mixture was extracted once with MTBE (5.0 volumes). The reaction mixture was extracted again with MTBE (3.0 volumes) (the solids at the interface were separated into the aqueous phase). All MTBE phases were combined and washed with water (2*2 volumes). The MTBE phase was concentrated to 2-2.5 volumes under vacuum at below 40°C. Heptane (5 volumes) was added to the residue and concentrated to 3-3.5 volumes under vacuum at below 40°C. Heptane (5 volumes) was added to the residue and concentrated to 3.5-4 volumes under vacuum at below 40°C. Heptane (5 volumes) was added to the residue and stirred for 6 hours at 15°C-25°C. Filter and wash the filter cake once with n-heptane (0.5 volume). Collect the filter cake and dry it under vacuum until KF≤0.5%, then sample it for LOD and report the result. Collect the product to obtain an off-white chiral solid (1R, 2R)-2-(dibenzylamino)cyclobutane-1-ol (61.93 kg, KF: 0.1%, LOD: 0.75%, HPLC purity: 99.9%, chiral purity: 99.7%, isolated yield: 33.5%).

[0506] (1R,2R)-2-(Dibenzylamino)cyclobutan-1-ol was converted to (1R,2R)-N,N-dibenzyl-2-methoxycyclobutan-1-amine according to the following sequence: 2Under protection, 2-MeTHF (588kg, 12.0 volumes) was added to a 2000L glass-lined reactor. Stir for 15 minutes and add (1R, 2R)-2-(dibenzylamino)cyclobutan-1-ol (57.0kg, 1.0 equivalent) to the reactor. Stir for 20 minutes to obtain a clear solution. The reaction system was cooled to -5°C to 0°C. t-BuOK (33.52kg, 1.4 equivalents) was added to the reactor in several batches at 0°C ± 5°C. Stir at 0°C-5°C for 2 hours. CH 3 I (42.35 kg, 1.4 equivalents) was added dropwise to the reactor. Stirred for 4 hours at 5°C ± 5°C. Soft water (5.0 volumes) was added at 0°C-30°C and stirred for 30 minutes. The organic layer was separated and collected. The aqueous layer was extracted with MTBE (3 volumes). The organic phases were combined and washed with soft water (2*2.5 volumes). Washed with brine (2.5 volumes) (the emulsion layer was collected separately when washed with brine). The emulsion layer was extracted with MTBE (2 volumes). The organic layers were combined. Filtered through an activated carbon filter. The organic layer was concentrated to 4-6 volumes under a vacuum of no more than 50°C. Methanol (10.0 volumes) was added to the reactor and concentrated to 4-6 volumes under a vacuum of no more than 55°C (jacket temperature). Methanol (10.0 volumes) was added to the reactor and concentrated to 4-6 volumes under a vacuum of no more than 55°C (jacket temperature). The concentrated residues were collected to give a solution of (1R,2R)-N,N-dibenzyl-2-methoxycyclobutan-1-amine in MeOH. HPLC purity: 99.9%.

[0507] Compound 5 was prepared from (1R,2R)-N,N-dibenzyl-2-methoxycyclobutane-1-amine according to the following sequence: 2 Under N atmosphere, a solution of (1R,2R)-N,N-dibenzyl-2-methoxycyclobutane-1-amine (30.0 kg, calculated at 100% conversion) in MeOH (about 150 L, 5 volumes, from the previous sequence) was added to a 1000 L autoclave, followed by MeOH (14 volumes). 2 20% Pd(OH) was wetted in the atmosphere 2 / C (50% water content, 3.0 kg, 0.1 w / w, based on wet weight) was added to the autoclave, and then the feed port was flushed with MeOH (1.0 volume). Stir and add H 2 (1.0 MPa) was added to the autoclave. Stirred at 20°C-30°C for about 24 hours. Filtered and 2The filter cake was washed with MeOH (3*1.0 volume) under atmosphere. The filtrate was collected. 4.0N HCl (g) in MeOH (2.0 equivalents) was added dropwise to the filtrate at 20°C-30°C. Stir for 2 hours at 20°C-30°C. Another batch was combined. The reaction mixture was concentrated to 3.5-4.5 volumes. Toluene (5.0 volumes) was added, and the reaction mixture was then concentrated to 3.5-4.5 volumes. The process was repeated once more to remove water from the mixture. A sample was taken for KF (standard: 0.10%, result: 0.07%). MTBE (5.0 volumes) was added, and the reaction mixture was then concentrated to 5.5-6.5 volumes, and then MTBE (1 volume) was added. Stir for 3 hours at 15°C-25°C. Filter and wash the filter cake with MTBE (2 volumes). The filter cake was collected and dried under vacuum at 40°C-50°C for 16 hours. The filter cake was collected to obtain a light pink solid compound 5 (26.92 kg, purity: 98.1 (GC), chiral purity: 99.9% (by derivatization), KF: 0.1%, isolated yield: 91.8%).

[0508] Step 3: Synthesis of compound 1

[0509]

[0510] Compound 2 (1.5 Kg, 2.68 mol, 1.00 equiv) in 3.3 M HCl / EtOH solution (19.1 Kg, 30.6 L, 15 volumes) was added to a 100 L reactor at 40°C ± 5°C. The reaction was completed after 21 hours at 40°C. HPLC (UV 266 nm) analysis of the reaction mixture showed 99.55% of the product compound 1. No peak of the starting material compound 2 was detected in the HPLC. The major impurity peak of the reaction mixture (0.32%) was located at 6.932 minutes (RRT: 0.454). This impurity peak also appeared in the HPLC using the test reaction (0.29%, RRT 0.47), and the impurity was completely removed after filtering the compound 1 HCl salt.

[0511] Filtration of HCl salts

[0512] Once the reaction is confirmed to be complete, the mixture is cooled to 20°C ± 5°C and stirred at 20°C ± 5°C for at least 30 minutes. Compound 1 HCl salt is collected by filtration. Filtration is very slow and requires 5.6 hours to filter. The wet cake is washed with EtOH (first wash: 1.8 Kg, second wash: 0.8 Kg).

[0513] Use K 2 CO 3 Neutralization of aqueous solution

[0514] Suspend the HCl salt of compound 1 in 0.5NK2 CO 3 The mixture was stirred at 20°C ± 5°C for at least 1 hour and a pH of 1.85 was observed. An additional amount of 0.5 Kg of 2 CO 3 Aqueous solution (42.1Kg) was added until pH ≥ 10 (actual pH: 10.05) was observed. The mixture was stirred at 20°C ± 5°C for at least 12 hours (actual stirring time: 17 hours). Solids were collected by filtration. Filtration was very slow and 5.9 hours were required to filter. The wet cake was washed twice with water (first wash: 3.0Kg, second wash: 4.5Kg). The wet cake was returned to the 100L reactor and re-slurried in water (17.0Kg) for 1 hour. Solids were collected by filtration. The wet cake was washed with water twice (first wash: 4.5Kg, second wash: 1.1Kg) and EtOH (1.2Kg). The wet cake was dried in a tray dryer at ≤ 60°C for at least 16 hours.

[0515] Dryness test(1): After drying at 58°C for 16.4 hours, a sample was taken out for KF test for reference only (KF result: 12.55%).

[0516] Dryness test (2): After drying at 58°C for another 23.2 hours (total: 39.6 hours), a second sample was taken for KF testing for reference only (KF result: 1.12%). This operation was biased (deviation report #19-111). The material was packaged and 1.14 Kg of compound 1 was obtained with a yield of 92.7% (before form conversion).

[0517] Form transformation

[0518] The dry solid compound 1 (1.14 Kg) was transferred to a 22 L glass reactor and EtOH (8.99 Kg, 11.4 L, 10 volumes relative to 1.14 Kg solid) was added. The mixture was stirred at 60°C ± 5°C for 3 hours. After cooling to 20°C ± 5°C and stirring at 20°C ± 5°C for 9.5 hours, a sample was taken and XRPD analysis showed crystalline material.

[0519] Solids were collected by filtration. The filter cake was transferred to a lined tray and dried in a tray dryer at ≤60°C for at least 16 hours. After drying at 57°C for 92.7 hours, a sample was taken out for LOD test, which showed that LOD was 0.20%. The material was considered to be dry and packaged. 1.1Kg of compound 1 was obtained as an off-white solid, with a 96.5% recovery rate. The overall yield of step 3 (including reaction, neutralization and form conversion) was 89.4%.

[0520] NMR peak assignment of compound 1

[0521] Numbering system for NMR peak assignments:

[0522]

[0523] Table 1: Compound 1 1 H-NMR spectrum and the same 13 Attribution of signals in C-NMR spectrum

[0524]

[0525]

[0526] Table 2: Characteristic absorption bands in the infrared spectrum of compound 1 and their attributions

[0527] Absorption band Attribution <![CDATA[3350cm -1 ]]> NH <![CDATA[3283cm -1 ]]> NH <![CDATA[1647cm -1 ]]> Amide or 2-pyridone carbonyl

[0528] Although the applicant has described many embodiments, it is apparent that the basic examples can be altered to provide other embodiments utilizing the compounds and methods described. It should be understood, therefore, that the scope of the invention is defined by the appended claims rather than by the specific embodiments represented by the examples.

Claims

1. A method for preparing compound 1: or a pharmaceutically acceptable salt or solvate thereof, the method comprising making a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group.

2. The method according to claim 1, further comprising: The following steps are involved: a) making a compound of formula II: or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; and compound 4: or a pharmaceutically acceptable salt thereof to produce a compound of formula I; as well as b) making the compound of formula I: or a pharmaceutically acceptable salt thereof.

3. The method according to claim 2, further comprising: The following steps are involved: a) the compound of formula III: or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; using compound 5: or a pharmaceutically acceptable salt thereof; To produce the compound of formula II; b) making the compound of formula II: or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; and compound 4: Cross-coupling to produce the compound of formula I; and c) making the compound of formula I: or a pharmaceutically acceptable salt thereof is deprotected to produce Compound 1.

4. The method of any one of claims 1 to 3, wherein PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl.

5. The method of any one of claims 1-4, wherein PG is tert-butyloxycarbonyl (BOC).

6. The method of any one of claims 1 to 5, wherein the compound of formula I is compound 2: or a pharmaceutically acceptable salt thereof.

7. The method of any one of claims 2 to 6, wherein the compound of formula II is compound 6: or a pharmaceutically acceptable salt thereof.

8. The method of any one of claims 3 to 7, wherein the compound of formula III is compound 7: or a pharmaceutically acceptable salt thereof.

9. A method for preparing a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group, the method comprising making a compound of formula II: or a pharmaceutically acceptable salt thereof, and compound 4: or cross-coupled with a pharmaceutically acceptable salt thereof.

10. The method of claim 9, further comprising: include: a) the compound of formula III: or a pharmaceutically acceptable salt thereof, using compound 5: or a pharmaceutically acceptable salt thereof; to produce the compound of formula II; and b) making the compound of formula II: or a pharmaceutically acceptable salt thereof, and compound 4: or a pharmaceutically acceptable salt thereof, To produce the compound of formula I.

11. A method for preparing a compound of formula II: or a pharmaceutically acceptable salt thereof, wherein PG is a suitable amino protecting group; the method comprises treating a compound of formula III: or a pharmaceutically acceptable salt thereof, using compound 5: or a pharmaceutically acceptable salt thereof is amidated; to produce the compound of formula II.

12. The method of any one of claims 9-11, wherein PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl.

13. The method of any one of claims 9-12, wherein PG is tert-butyloxycarbonyl (BOC).

14. The method of claim 9 or 10, wherein the compound of formula I is compound 2: or a pharmaceutically acceptable salt thereof.

15. The method of any one of claims 9 to 14, wherein the compound of formula II is compound 6: or a pharmaceutically acceptable salt thereof.

16. The method of any one of claims 10-15, wherein the compound of formula III is compound 7: or a pharmaceutically acceptable salt thereof.

17. A compound 1 or a pharmaceutically acceptable salt or solvate thereof, produced by the method of any one of claims 1-8:

18. A compound of formula I: or a pharmaceutically acceptable salt or solvate thereof, in: PG is a suitable amino protecting group.

19. The compound of claim 18, wherein the compound of formula I is compound 2: or a pharmaceutically acceptable salt thereof.

20. A compound of formula II: or a pharmaceutically acceptable salt or solvate thereof, in: PG is a suitable amino protecting group.

21. The compound of claim 20, wherein the compound of formula II is compound 6: or a pharmaceutically acceptable salt or solvate thereof.

22. The compound of claim 18 or 20, wherein PG is tert-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl or benzoyl.

23. The compound of any one of claims 18, 20 or 22, wherein PG is tert-butyloxycarbonyl (BOC).

24. A method of inhibiting TYK2 protein kinase or a mutant thereof in a patient, the method comprising administering to the patient a therapeutically effective amount of Compound 1: or a pharmaceutically acceptable salt or solvate thereof, wherein Compound 1 is produced by the method of any one of claims 1-8.